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Abstract: After an acute ischemic stroke (AIS), inflammatory processes are able to concomitantly
induce both beneficial and detrimental effects. In this narrative review, we updated evidence on
the inflammatory pathways and mediators that are investigated as promising therapeutic targets.
We searched for papers on PubMed and MEDLINE up to August 2016. The terms searched alone or
in combination were: ischemic stroke, inflammation, oxidative stress, ischemia reperfusion, innate
immunity, adaptive immunity, autoimmunity. Inflammation in AIS is characterized by a storm of
cytokines, chemokines, and Damage-Associated Molecular Patterns (DAMPs) released by several
cells contributing to exacerbate the tissue injury both in the acute and reparative phases. Interestingly,
many biomarkers have been studied, but none of these reflected the complexity of systemic immune
response. Reperfusion therapies showed a good efficacy in the recovery after an AIS. New therapies
appear promising both in pre-clinical and clinical studies, but still need more detailed studies to be
translated in the ordinary clinical practice. In spite of clinical progresses, no beneficial long-term
interventions targeting inflammation are currently available. Our knowledge about cells, biomarkers,
and inflammatory markers is growing and is hoped to better evaluate the impact of new treatments,
such as monoclonal antibodies and cell-based therapies.
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1. Introduction
The World Health Organization defined “stroke” as a clinical syndrome characterized by a rapid
onset of focal (or global in the case of coma) cerebral deficit lasting more than 24 h or leading to death,
due to a vascular ischemic cause [1]. Ischemic stroke (IS) accounts for the majority of strokes and
includes cryptogenic, lacunae, and thromboembolic strokes and it occurs usually when the blood
supply to an area of the brain is interrupted [2]. Classical risk factors include age, cigarette smoking,
diabetes, hypertension, and obesity. Prone-to-embolism diseases, such as cardiac valve disease and
atrial fibrillation, increase the risk for IS, with the latter representing the most frequent condition.
In IS, inflammation plays a pivotal role exerting both beneficial and detrimental effects (Figure 1).
In fact, activation of resident cells, such as microglia, astrocytes, and endothelial cells is neuroprotective
and promotes brain regeneration and recovery, whilst the recruitment of immune cells expressing
inflammatory mediators and leading to blood-brain barrier (BBB) disruption is responsible for neuronal
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death, brain edema, and hemorrhagic transformation [3]. The sudden blockage of blood flow to the
brain causes tissue hypoxia and triggers an inflammatory cascade leading to impairment of ion
homeostasis, neuronal excitotoxicity, intracellular calcium overload, free radical generation, and lipid
peroxidation ultimately determining neuronal injury [4]. The aim of the therapy is to mechanically
or pharmacologically restore the blood flow as soon as possible to limit tissue damage. However,
strangely, blood restoration is often associated with an exacerbation of tissue injury and a deep
inflammatory response called “reperfusion injury” [5,6]. In this narrative review, based on papers
found on PubMed and MEDLINE up to August 2016 (searched terms: ischemic stroke, inflammation,
oxidative stress, ischemia reperfusion, innate immunity, adaptive immunity, autoimmunity; articles
were also found through searches of reference lists and the authors’ files), we have updated the
evidence regarding inflammatory cells, biomarkers, and pathways during and after an IS and speculate
about new, potential therapeutic perspectives in order to reduce the detrimental effects carried by
ischemia/reperfusion (I/R) in the brain following an IS.
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Figure 1. Mechanisms of neuronal death in acute ischemic stroke. After brain ischemia occurs,  
a reduction in the oxygen and glucose supply is carried out leading to the depolarization of 
membranes and finally to a great increase in intracellular calcium concentration and release of 
glutamate. Glutamate receptors, once activated, are responsible for the further increase in calcium 
concentration. The detrimental effects of this huge calcium concentration are proteolysis, lipolysis, 
mitochondrial damage, and increase in nitric oxide synthase activity. Despite the re-oxygenation 
should favor the recovery, it triggers reactive oxygen species production, amplifying the damage, 
ultimately leading to death of neuronal cells. Ca2+: calcium. NOS: nitrix oxide synthase. ROS: reactive 
oxygen species. 
2. Inflammatory Cells Involved in Post-Ischemic Brain Injury and Repair 
The ischemic and reperfusion periods are both characterized by pathophysiological alterations, 
involving the modulation of inflammatory cell function [7]. In the following sub-paragraphs, we will 
update evidence on the major inflammatory cell subsets. 
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2. Inflammatory Cells Involved in Post-Ischemic Brain Injury and Repair
The ischemic and reperfusion periods are both characterized by pathophysiological alterations,
involving the modulation of inflammatory cell function [7]. In the following sub-paragraphs, we will
update evidence on the major inflammatory cell subsets.
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2.1. Neutrophils
Already few hours after the stroke onset, the number of circulating polymorphonuclear
neutrophils (PMNs) rise in a stroke severity-dependent manner [8] as a result of different mechanisms:
an increased release from the bone marrow and spleen reserves, an enhanced production, and a reduced
apoptosis [9]. PMN rolling and adhesion have been described early after stroke onset in arterial
vessels of the brain [10] due to the up-regulation of circulating and endothelial chemoattractants and
adhesion molecules [11]. Early adhesion molecule-mediated PMN migration through brain vessels
and parenchymal infiltration at ischemia site is now under discussion [11]. Recently, in experimental
models and in human specimens it has been demonstrated that during the acute phase of reperfusion,
PMNs are not found in the ischemic parenchyma, but remain in the neurovascular unit (NVU) and in
the leptomeningeal spaces [12,13]. Here, they are attracted by accumulated signals released by ischemic
brain in the interstitial fluid and then drained through perivascular spaces of cortical arterioles toward
leptomeninges [12]. Accordingly, in vitro, ischemia alone was not able to induce PMN migration
through BBB [13]. Only after prolonged ischemia (12 h), PMNs have been detected in cortical infarcted
parenchyma [10].
Innate immune system answers to the cerebral damage through PMN activation attempting beneficial
effects (e.g., contributing to resolution of inflammation, scar formation, and neo-angiogenesis) [14–16],
but in this way contributing to BBB impairment and cerebral edema (Figure 2) [17]. PMN accumulation
in the damaged tissue correlates with stroke severity and worst stroke outcome [18]. Activated
PMNs enhance ischemic damage mainly through three mechanisms, such as reactive oxygen species
(ROS) and protease production [19], cytokine-mediated enhanced inflammation, and complement
activation [20]. On the basis of these findings, several studies tried to improve stroke outcomes by
blocking PMN activation and recruitment, reducing their adhesion to endothelial cells or blocking
mediators of BBB damage [21]. The complex relationship between PMNs, ischemic stroke, reperfusion
injury, and the augmented infective risk following anti-neutrophil treatment explain the high rate of
treatment failure and discrepancies hanging over these attempts.
2.2. Microglial Cells and Circulating Monocytes/Macrophages
Soon after IS onset, microglia (including Brain Res.ident macrophages) is activated and
enhances circulating monocyte recruitment by releasing pro-inflammatory mediators, such as tumor
necrosis factor (TNF)-α, nitric oxide (NO), and superoxide (Figure 2) [3]. Among different possible
microglia-activating stimuli, released adenosine triphosphate from damaged cells seems to play
an important role in animal models [22]. Microglia activation exerts both beneficial and detrimental
effects on stroke outcomes. Once activated, in fact, resident macrophages can polarize toward different
phenotypes in response to local ischemic milieu ranging from classically activated, pro-inflammatory
macrophages type 1 (M1) to alternatively activated macrophages type 2 (M2), which are mainly
involved in the resolution of inflammation and tissue healing (Figure 2) [23]. On the other hand,
microglia inhibition in experimental models of brain injury leads to contradicting results in terms of
neuronal survival [24–27].
In contrast to early microglial response, monocyte-derived macrophages from bloodstream reach
the damaged site most abundantly 3–7 days after ischemia onset during the chronic phase of IS [28].
Early after brain injury, an increased number of total monocytes in the blood circulation has been
described in humans [29]. About different subtypes, classical monocyte subset (CD14++ CD16−)
significantly increased, while the non-classical monocyte subset (CD14+ CD16++) significantly
decreased [29]. Progression and severity of brain ischemia directly correlate with CD14++ CD16−
increase and CD14+ CD16++ reduction [29]. As already known in another model [30], the splenic
monocyte reserves were critical in the pathophysiology of brain infarction [31,32]. Although different
studies reported that splenectomy or spleen irradiation reduced ischemic cerebral injury in animal
models [33–35], some concerns rise from a work by Kim and colleagues [36]. In this study, spleen
contraction after brain injury was accompanied by decreased number of Ly-6Chigh and Ly-6Clow
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subsets in the spleen and temporally coincided with respective increases in the ischemic brain. Despite
the reduced accumulation of both subsets in injured brain, splenectomy failed to reduce infarct size and
swelling. Subset-specific studies and more homogeneity in stroke model (e.g., permanent vs. transient
artery occlusion) are needed to fully address spleen function in brain infarction.
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Figure 2. Inflammatory cells in post-ischemic brain injury and reparation. Inflammatory mediators
released by the ischemic zone promote neutrophil activation and recruitment with a resulting effect
on the blood-brain barrier and brain parenchyma. Resident macrophages of the brain (microglia) and
circulating monocytes are early involved in the inflammatory response through an M1-switching with
production of inflammatory mediators, such as reactive oxygen species, matrix metalloproteinases
(MMPs), cytokines, and chemokines. Both neutrophils and macrophages (in particular M2 phenotype)
are involved in late resolution through the production of anti-inflammatory and pro-angiogenic
mediators. The adaptive immunity contribution is partly mediated by lymphocytes. CD4+, CD8+,
and γδ T cells play a detrimental role, while Treg and Breg lymphocytes are involved in the resolution
phase. IL: interleukin; TNF-α: tumour necrosis factor α; CCL: C-C motif chemokine ligand; VEGF:
vascular endothelial growth factor; TGF-β: transforming growth factor β; IFN-γ: interferon γ.
Peripheral monocyte heterogeneity corresponds to the presence of different macrophage subsets
in the infarcted parenchyma, where these cells can shift from a p enotype to another depending on
the local milieu [37]. Although exact contribution of different cellular subs ts on lesion evolution
is still elusive, the early monocyte recruitment at stroke he isphere has be n demonstrated to
mainly i volve pro-inflammatory Lys6Chigh cells. Once in t e rebral tissue, these cells wer shown
to differentiate into anti- nflammatory patrolling onocytes [38]. Moreover, selective depletion
of Lys6Chigh was associated with increased hemorrhagic transfo mat ons through the rupture
of n o-vessels within infarct peripheral zone [38]. Accordingly, Chu and co-workers recently
demonstrated that pro-inflammatory monocytes infiltrating ischemic lesion were able to differentiate
into M2 anti-inflammatory monocyte-derived acrophages, in ucing the same translation to adj cent
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monocyte-derived macrophages or microglia [39]. A deeper spatial, temporal, and functional
characterization of different mononuclear cell subtypes is needed to provide more clear translational
evidences guiding future potential interventions.
2.3. T and B Lymphocytes
Antigen-specific and antigen-independent mechanisms were shown to activate
T lymphocyte-mediated response after an IS [40,41]. T cells have been also detected in the
infarction boundary zones early within 24 h after reperfusion, then they accumulate until day 7 and
decrease in number after 14 days [42]. Among different T lymphocyte subsets, both CD4+ and CD8+
seem to play a harmful role in the infarcted parenchyma (Figure 2) [43]. Moreover, Shichita and
colleagues showed in a murine stroke model that interleukin (IL)-17 plays an important role in the
delayed phase of I/R injury during which apoptotic neuronal death occurs in the penumbra [44].
γδ T cells have been identified as the main source of this cytokine [44]. Similarly, also human infarcted
brain showed high levels of IL-17 [45]. Thus, γδ T cells and IL-17 are interesting therapeutic targets to
reduce neuronal death in I/R brain injury.
T regulatory (Treg) cells were suggested to play an opposite role from other T cells subsets.
These cells are important regulators of immune homeostasis through direct interaction with other cells
and production of anti-inflammatory cytokines, such as IL-10 and transforming growth factor (TGF)-β.
The selective depletion of Treg cells was associated with an increase in infarct size and behavioral
deficits after brain ischemia in an experimental model of stroke, whilst beneficial effects of Treg cells
were mediated by IL-10 via abrogation of interferon (IFN)-γ-mediated pathways (Figure 2) [46].
B cell effects on I/R brain injury are mainly related to autoantibody production as detailed in the
following paragraphs. Regulatory B cells showed the capacity to reduce inflammation and neurological
deficits in a murine stroke model, while abrogation of this cell subset was accompanied by an enhanced
brain infiltration by different leukocyte subpopulations (Figure 2) [47].
3. Soluble Mediators of Post-Ischemic Brain Injury
3.1. Cytokines
A variety of cytokines triggers the inflammatory response to ischemic brain injury. The most
important, pro-inflammatory cytokines are TNF-α, IL-1, and IL-6, which were detected within
the brain, the cerebrospinal fluid (CSF), and the blood of patients suffering from acute IS and are
responsible for the extension of the infarct zone in animal models [48]. Many studies demonstrated
that cytokine-mediated effects on ischemic area are strictly related to a huge increase of their levels,
considering that infarcts reach their final volume many hours before cytokines peak [49,50]. It is
very interesting to underline that even smaller increases in cytokine levels were shown to impact on
the tissue injury evolution [48]. TNF-α owns a dual role: it can both exacerbate and reduce infarct
evolution. TNF-α blocking with specific monoclonal antibodies confers neuroprotection [48]. On the
other hand, TNF-α produced by microglial cells was protective on ischemic neurons [51].
IL-1 is a pro-inflammatory cytokine, which exists in two forms, IL-1α and IL-1β. Both forms
signal through the IL-1 receptor type I, which can be competitively blocked by the receptor antagonist
(IL-1Ra) [52]. Both IL-1α and IL-1β levels are elevated in the first hours following an IS. IL-1α is
mainly secreted by microglia, while IL-1β is released by different compartments of the NVU [53]. It is
surprising to note that IL-1 is not directly toxic, but it is able to activate astrocytes and endothelium
favoring astrogliosis, release of chemokines, activation of metalloproteinase (MMP)-9, and release of
vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 [54–56].
IL-10 and TGF-β behave as anti-inflammatory cytokines, favoring the tissue recovery [57].
In particular, IL-10 was demonstrated to act as a down-regulator of the negative effects carried
by pro-inflammatory cytokines modulating neuronal vulnerability to excitotoxicity induced by
ischemia [58,59]. Blood levels of TGF-β increased the day after IS and remained elevated in astrocytes
and microglia/macrophages for at least one week in animal models [60,61].
Int. J. Mol. Sci. 2016, 17, 1967 6 of 53
With regard to cytokine levels in CSF and bloodstream, the peak of TNF-α in CSF at 24 h after IS
correlated with clinical outcomes. Other studies also indicated that increased levels at 6 h correlated
with stroke severity [62,63]. On the contrary, IL-1β levels were increased in CSF after 6 h, but they did
not correlate with infarct size or clinical outcome [63]. In the bloodstream, data on TNF-α and IL-1β
levels were controversial [64].
The high heterogeneity of results on cytokine levels indicates that systemic inflammation has
a poor clinical value to predict IS clinical evolution.
3.2. Chemokines
The three most relevant chemokines that might play a pathophysiological role after IS are:
stromal cell-derived factor (SDF)-1, also known as C-X-C motif chemokine (CXCL)12; fractalkine,
also known as C-X3-C motif chemokine ligand (CX3CL)1; and monocyte chemoattractant protein
(MCP)-1, also known as C-C motif chemokine ligand (CCL)2.
The blockade of CXCL12 binding to its receptor (C-X-C chemokine receptor type 4) was
demonstrated to reduce inflammation and infarct size in animal models. In particular, leukocyte
infiltration and cytokine release were markedly reduced and BBB disruption was also limited [65,66].
Besides, in animal models CXCL12 expression demonstrated to be useful for the recovery [67]. CXCL12
was also shown to promote bone marrow-derived cell targeting to injured cells and improve local
blood flow facilitating post-ischemic brain recovery [68].
Results from IS models demonstrated that the abrogation of the binding between CX3CL1
and its receptor (CX3CR1) on microglial cells leads to a reduced post-ischemic damage in terms of
excitotoxicity, ROS release, BBB disruption, and leukocyte infiltration [69–71]. However, other studies
highlighted beneficial effects correlating high plasmatic concentrations of CX3CL1 and good clinical
outcomes [70,72]. Interestingly, Rosito and co-workers proposed that the release of chemokines, such as
CX3CL1, CXCL16, and CCL2 affects neurons, microglia, and astrocytes during brain ischemia [73].
These molecules might be considered as endogenous self-protective compounds limiting the cell
damage in the ischemic penumbra [73].
Antagonism and neutralization of the binding between CCL2 and its receptor (CCR2)
was associated with a decrease in leukocyte infiltration within the infarcted area and a BBB
impairment [74,75]. Strecker and colleagues hypothesized that the reduced permeability of BBB
in Ccl2-knockout mice could be linked to transcriptional effects of CCL2 on BBB-related genes,
such as occludin, zonula occludens-1, and zonula occludens-2 [76]. CCL2/CCR2 interaction was
demonstrated to stop the hemorrhagic transformation via the recruitment of bone marrow-derived
monocytes/macrophages and especially by preserving the integrity of the NVU via a TGF-β-triggered
pathway [38]. Moreover, CCL2 was found to promote the migration of neuroblasts from neurogenic
regions to ischemic damaged areas [77]. As for other chemokines, CCL2 owns detrimental properties,
too. Indeed, CCL2 is involved in the recruitment of inflammatory cells exacerbating the brain
injury [78,79].
3.3. Reactive Oxygen Species
After an IS, the up-regulation of antioxidant enzymes was not described to efficiently counteract
the huge increase in reactive oxygen species (ROS) generation. This redox unbalance triggers early
inflammatory responses, involving both microglial and neuronal cells, as well as circulating leukocytes
(Figure 3) [80]. ROS are essential mediators in the inflammatory environment whose major source is
nicotinamide adenine dinucleotide phosphate hydrogen oxidase (NOX) [81] together with immune
cells infiltrating ischemic tissue [82]. ROS generation stimulates ischemic neurons to release in turn
additional ROS via other enzyme systems [83]. Different isoforms of NOX have been described in
mammalians, which are the NOXs (NOX1-, NOX2-, NOX3-, NOX4-, and NOX5-containing oxidases)
and the dual oxidases (DUOX1- and DUOX2-containing enzymes) [84].
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NOX1 and NOX2 showed to enhance vascular pathology, while NOX4 contributed to vascular
protection [85,86]. NOX1- and NOX2-derived ROS contribute to vascular disease mainly because of NO
inactivation and oxidative damage. In fact, ROS are responsible for the inactivation of NO mediated by
superoxide and also for the formation of peroxynitrite, causing irreversible damages to macromolecules,
such as DNA, proteins, and lipids [86]. Moreover, peroxynitrite can interact with the endothelial nitric
oxide synthase (eNOS) cofactor, tetrahydrobiopterin; in the absence of tetrahydrobiopterin, eNOS is
enzymatically uncoupled and generates superoxide, contributing to increase the oxidative stress [84].
NOX2 deletion in mice was demonstrated to reduce the infarct size and the effect might involve
both circulating neutrophils and Brain Res.ident cells [87]. The vasoprotective effect of NOX4 is not
yet fully understood, but it might depend on the production of hydrogen peroxide. This product
does not react with NO at the same manner as superoxide (produced by NOX1 and NOX2) and
consequently does alter significantly its bioavailability. Moreover, NOX4 is considered an important
signaling mediator capable to modify the function of some proteins by reversibly oxidizing reactive
cysteine residues [88]. Finally, NOX4 overexpression was demonstrated to augment eNOS expression
and activity in a catalase-dependent way promoting angiogenesis and recovery from hypoxia [89].
Nevertheless, post-stroke inhibition of NOX4 in mice has proved to be exceptionally neuroprotective,
resulting in improved long-term neurological functions and reduced mortality [90].
Through a variety of upstream molecules, ROS activated different pathways leading to dual
actions, either detrimental or beneficial. Once generated, ROS can cause microvascular occlusion
and cross the vessel wall reacting with macromolecules finally leading to lipid peroxidation, protein
oxidation, and DNA damage [91]. The phagocytic burst triggered by ROS is also responsible for
the derangement of BBB explaining the typical post-ischemic complications, such as brain edema
and hemorrhagic transformation. Neutrophils release a relevant amount of hydroxyl radical, which
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is blocked by hyperbaric oxygenation and by oxidant scavenger [92]. ROS of neutrophil origin are
responsible for I/R injury; hydroxyl radical is able to sensitize the mitochondrial permeability transition
pore activity enhancing calcium overload leading to the blocking of the mitochondrial respiratory
chain and finally to neuronal death. Moreover, ROS are directly responsible for neuronal cell apoptosis
via different inflammatory pathways as displayed in Figure 2. Microglial cells can generate ROS via
NOX1 and NOX2 activation [93,94]. Astrocytes can reduce oxidative stress by the activation of the
nuclear factor-erythroid 2-related factor 2-dependent pathway [95]. Finally, brain microvascular cells
are capable of releasing ROS and triggering BBB dysfunction by lipid peroxidation [96].
3.4. Damage-Associated Molecular Patterns (DAMPs)
These endogenous molecules are released from injured cells after the ischemic trigger and induce
the activation of Toll-like receptors (TLRs) and some others, such as receptor for advanced glycation end
products (RAGE), and c-type lectin receptors, finally amplifying inflammatory mediator expression and
tissue damage [97]. Mitochondrial DNA released by ischemic neurons is detected from immune cells
as DAMPs and is capable to activate TLR9 [98]. Mitochondrial DAMPs include formyl peptides and
mitochondrial DNA itself and are able to activate human neutrophils through formyl peptide receptor-1
and TLR9. Moreover, they stimulate neutrophil calcium influx and phosphorylation of MAPK, allowing
neutrophil migration and degranulation both in vitro and in vivo. Maeda and colleagues demonstrated
that intact mitochondria are released from cells undergoing necroptosis induced by TNF-α [99]. Human
macrophages and dendritic cells have been shown to overwhelm mitochondria from necroptotic cells
leading to macrophage secretion of cytokines and dendritic cell maturation [99]. Self RNA and DNA
alongside with the LL37 peptide are able to activate an immune response through TLR7 and TLR9 [100];
TLR7 was also associated with a greater deterioration in IS with regard to TLR9 [101]. Both purines and
their receptors, such as the P2Y receptor G protein-coupled receptor 17, are to be considered danger
signals activating responses to tissue damage [102]. Also adenosine triphosphate can stimulate the
activation of inflammasomes, whose activation leads to the amplification of post-ischemic injury and
finally to neuronal death [103].
During lipid peroxidation, final products are yielded, such as phosphatidylcholine,
malondialdehyde, and 4-hydroxynonenal. They are reactive aldehydes forming covalent adducts with
primary amines of proteins and amino groups of lipids, such as phosphatidylethanolamine, thereby
leading to the so-called oxidation-specific epitopes (OSEs). OSEs are usually recognized by different
receptors in a hapten-specific manner activating adaptive immunity responses and for this reason have
been proposed as a new type of DAMPs [104]. Phospholipids after oxidization have been considered
DAMPs; they are CD36 ligand and have been described to promote inflammation via TLR2 in ischemic
brain [105]. Oxidized phospholipids can also activate the inflammasome and two different pathways
both ROS-dependent and ROS-independent have been implicated [106,107].
High mobility group box 1 (HMGB1) and peroxiredoxin (Prx) family proteins are two relevant
DAMPs involved in brain ischemia. Typically, HMGB1 was described at the very early phases of
stroke, whilst Prx was found at the subacute phase, mainly in the penumbral area. HMGB1 is a nuclear
protein functioning as nucleosome stabilizer and transcription-factor like-protein. HMGB1 is actively
secreted by macrophages, dendritic cells, and natural killer cells after acetylation through a mechanism
partially depending on lipopolysaccharide (LPS)-mediated signaling through the TLR4-CD14 complex,
TNF-α, and TGF-β. HMGB1 can also be passively released by necrotic cells following an injurious
stimulus [108]. HMGB1 is used to interact with RAGE on endothelial cells, activating them and
increasing VCAM-1, ICAM-1, and E-selection expression, thus facilitating neutrophil and monocyte
adhesion to the endothelium and further neutrophil recruitment [108]. However, RAGE expression
by endothelial cells can promote leukocyte recruitment through myeloid cells by the β2-integrin
macrophage receptor 1 (CD11b). Also activated macrophages express HMGB1 facilitating their
recruitment by binding RAGE at cell surface membrane [109]. HMGB1-RAGE signaling pathway has
been confirmed as a critical player after brain injury as its inhibition was shown to improve the systemic
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metabolic and behavioral consequences of brain ischemia and reduce mortality without affecting the
size of brain lesions [97]. Interestingly, Hu and co-workers investigated the HMGB1-RAGE pathway in
diabetic rats, showing its increase in brain ischemia together with a decreased functional outcome [110].
Nonetheless, the injection of bone marrow stromal cells significantly reduced the expression of HMGB1
and RAGE and enhanced functional outcome, as confirmed by in vitro data [110].
Prx has been explained to own two opposing functions, both inside and outside brain cells.
Ischemia increases Prx expression inside neural cells, favoring the survival of these cells by the ROS
catabolism. When ischemic stress finally ends in necrosis, Prx is released from necrotic cells into
the extracellular compartment and strongly stimulates macrophage infiltration via TLR2 and TLR4
inducing the inflammatory cytokine expression and the following ischemic injury. Over 24 h after
stroke onset, IL-23 induces IL-17 production from T cells aggravating ischemic damage. In this view,
HMGB1 can be considered a hyperacute DAMP, whereas Prx could act as secondary DAMP in the
acute phase of stroke [111].
S100A8, S100A9, and cold-inducible RNA binding protein were described as DAMPs, even if with
a lesser relevance, through the activation of TLR2, TLR4, and RAGE [112,113]. Heat shock protein gp96
is an endoplasmic reticulum chaperone for cell-surface TLR and was also considered as DAMP [114].
3.5. Autoantibodies
Very little is known about autoantibodies in the setting of IS. Most autoantibodies produced after
a central nervous system (CNS) injury are considered “natural” autoantibodies that could bind CNS
antigens. In fact, B1 cells are able to synthesize immunoglobulin (Ig)M autoantibodies binding multiple
antigens with low affinity, which are responsible for the clearing of aging and damaged cells [115].
Moreover, natural IgM autoantibodies have been described to improve re-myelination and block
neuronal apoptosis in animal models of multiple sclerosis [116]. Many autoantigens and autoantibodies
have been taught to cause or exacerbate neuronal injury during brain diseases. A possible explanation
for the production of autoantibodies following IS can derive from the neurological damage induced
by ischemia triggering a secondary immune response toward injured tissues or their components.
The prerequisite for antibodies to contribute to brain damage is the access to CNS, which could occur
during events accounting for a dysfunction of BBB, such as IS, hypertensive crisis, or lacunar stroke.
Bornstein and co-workers showed that autoantibodies to specific antigen, such as neurofilaments (NF)
but not to the ubiquitous antigen cardiolipin rose significantly in the first three months following
an IS [117]. This would be possible because antibodies toward brain-specific antigens could be
preferentially induced after IS on the basis of a different degree of immunologic tolerance. The clinical
relevance of antibodies to NF is not fully understood, but they have been demonstrated to play
a role in the development of human primary degenerative dementia, so that a similar role could
be played in the stroke-induced dementia [118]. Antibodies binding to subunits (NR2A/2B) of
N-methyl-D-aspartate receptor, too, have been found to be increased in patients with IS and transient
ischemic attack [119]. Interestingly, Kimura and colleagues showed a significant correlation between
anti-heat shock protein (Hsp) 60 antibody titer and the severity of white matter hyperintensities
on brain magnetic resonance, suggesting a potential role for Hsp60 as an active factor underlying
cerebral small-vessel disease [120]. Myelin basic protein (MBP) is a myelin-associated protein found
in oligodendrocytes. A powerful immune response toward MBP was triggered by Th1 lymphocytes
following an IS and was demonstrated to correlate with a poor clinical outcome at 90 days, even
when adjusted for National Institute of Health Stroke Scale (NIHSS) score and age [121]. Shibata and
colleagues evaluated Ig titers in patients with IS, noting that stroke was associated with a quick decrease
in the titer of anti-tetanus toxoid IgG antibodies; that patients with white matter disease showed higher
IgG antibodies titers to MBP and proteolipid protein; and finally confirmed the above-mentioned
findings by Becker and co-workers [121], showing worse long-term outcome in association with high
antibody titers to MBP. This latter evidence is very interesting suggesting the real possibility that some
antibodies do play a pivotal role in the pathophysiology of IS [122].
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3.6. Miscellaneous: Osteoprotegerin, Adipokines, and Osteopontin
Osteoprotegerin (OPG) is a secreted protein binding to receptor activator of nuclear factor-κB
ligand (RANKL) and inhibits RANK/RANKL pathway [123]. The OPG/RANK/RANKL axis plays
a role in bone metabolism and arterial calcification deposition [124]. Furthermore, it is expressed in
different immune cells suggesting an involvement in inflammation regulation [125,126]. OPG plasma
levels are higher in patients with IS compared with healthy individuals [127]. Moreover, OPG levels
are positively correlated with stroke severity and worse prognosis [127,128]. Guldiken and co-workers
pointed out a difference in OPG levels between IS subtypes, being significantly more elevated in
large-vessel disease than in small-vessel disease group [129].
Adipokines were shown to play a central role in vascular inflammation and seem to be involved
in the pathophysiology of several cardiovascular events, even in IS [130]. Serum levels of adiponectin
and leptin had differential association patterns with IS subtypes [130]. In a recent study by our
group, leptin levels increased rapidly after an IS. According to a previous study [131], our group was
able to suggest a neuroprotective effect of leptin in terms of clinical and radiological outcomes in
humans [132]. These clinical observations were supported by experiments using a rodent model of
IS, in which microglia and macrophages of the penumbra were shown to release leptin [133]. Leptin
may reduce cerebral injury after ischemia throughout other already identified mechanisms. Firstly,
leptin administration increased glucose uptake in neurons by the activation of phosphatidylinositol
3-kinase (PI3K)/Akt signaling pathway [134]. Secondly, an increase in neurogenesis and angiogenesis
in the perilesion cortex was observed after leptin treatment [135]. Thirdly, leptin was found to reduce
oxidative stress caused by the overproduction of ROS after reperfusion [136]. After peripheral leptin
administration, an increase in the level of anti-apoptotic Bcl-2 protein and a decrease in the level of
pro-apoptotic caspase-3 protein were seen [136].
Also adiponectin (APN) seems to have a neuroprotective role after IS. In a prospective study by
Efstathiou and co-workers, patients with lower APN levels showed worse outcomes after IS irrespective
of the presence of other adverse factors [137]. On the other hand, APN levels were inversely correlated
with the extent of infarcted area [137]. In animal models, APN overexpression reduced cortical atrophy
after an IS and increased focal angiogenesis by promoting adenosine monophosphate-activated protein
kinase signaling [138,139]. Finally, APN overexpression was demonstrated to improve neurobehavioral
outcomes, even in aged mice [138,139].
Osteopontin (OPN) is a secreted glycoprotein involved in the bone turnover and metabolism [140].
However, in the last decades, it has been investigated for its pro-inflammatory activity in chronic
inflammatory and cardiovascular diseases [140]. Several clinical studies on IS patients found a positive
correlation between OPN plasma levels and adverse long-term outcomes in terms of neurological
disabilities and infarct volume [141,142]. Although an active role of OPN in post-ischemic injury
was suggested, some in vivo and in vitro studies indicate a neuroprotective effect [143,144]. OPN
was shown to reduce ischemic cell death by the phosphorylation of Akt and the activation of
PI3K/Akt pathway [143]. In a recent study, the main source of OPN expression has been identified in
monocytes/macrophages infiltrating the infarct border area. Indeed, OPN was shown to play a role in
astrocyte polarization toward the lesion core, a key phase for BBB repair and resolution of vasogenic
edema [145].
4. Inflammatory Mediators as Potential Diagnostic or Prognostic Biomarkers
4.1. Clinical Evidence
As early diagnostic accuracy of brain computed tomography scan is only about 85%, many studies
in the last few years attempted at investigating the prognostic ability of inflammatory biomarkers
toward IS diagnosis as well as response to treatment and prognosis. However, an individual biomarker
validated for clinical use has not been identified yet. To be clinical useful an IS biomarker must
be sensitive to early ischemia and relatively specific for the brain. A good diagnostic biomarker
should also distinguish between different IS etiologies and exclude other conditions mimicking stroke,
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such as hypoglycemia, focal seizures, migraine, and psychogenic diseases. Furthermore, specific
challenges regarding biomarkers of central nervous tissue include the penetration of BBB and the lack
of correlation between functional symptoms and volume (as opposed to location) of injured tissue.
According to pathophysiological processes underlying IS, potential inflammatory biomarkers may be
classified as released by: (i) astroglial activation and neuronal injury (Table 1) [146–157]; (ii) systemic
inflammatory response (Table 2) [158–179]; (iii) dysfunctional endothelium (Table 3) [180–186]
(Figure 4).
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BBB breakdown after IS allows the permeability of proteins released by astrocytes and neurons
into the bloodstream [187]. Therefore, the measurement of these proteins might potentially be useful as
specific biomarker of IS (Table 1). Among them, the release of calcium-binding proteins S100B has been
traditionally ascribed to strocyte dysfunction, but recent studies rather indicat role as a marker of
BBB injury [188,189]. Serum l vels of S100B increase at 8–10 h from sympt m onset, reach the peak after
72 h and then drop in levels at 96 h [146]. However, a recent meta-analysis of 10 pooled case-control
studies failed to validate S100B as diagnostic marker of IS [147]. Instead, S100B was shown to predict
hemorrhagic transformation (HT) and long-term functional outcome [146,148]. Lipid peroxidation and
oxidative stress have been described as early events of neuroinflammation and then investigated as
prognostic markers of IS. The thiobarbituric acid reactive substances (TBARS) and the direct assay of
malonildyaldeide (MDA) have been identified as predictors of poor eurological outcome [149,150].
However, TBARS and MDA lack of specificity and their e surement is highly imprec se, likely
resulting in an overestimation of oxidative stress. Furthermore, the reliability of redox balance assay is
weakened by confounding factors (lifestyle, comorbidity, drug administration) and methodological
limitations involving sample handling, storage, and preparation [190]. The intracytoplasmic glycolytic
enzyme neuron-specific enolase (NSE) and the heart-type fatty acid binding protein (H-FABP) are
characterized by great specificity for brain tissue and early rise during the first 3 h after the symptom
onset [191–193]. However, the diagnostic accuracy of NSE and H-FEBP is affected by a low sensitivity
and their use is not recommended in clinical practice. NSE also correlated with stroke severity at
admission [151,152,154] and HT [155], whereas data on long-term outcomes are controversial [153,156].
Int. J. Mol. Sci. 2016, 17, 1967 12 of 53
Table 1. Brain-specific inflammatory biomarkers potentially useful in stroke diagnosis, response to treatment, and outcome.
Author Year Study Design Biomarker Outcome Results
Astroglial activation
Dassan et al. [146] 2009 Systematic review(13 longitudinal studies) S100B IS diagnosis HT mRS
S100B may be useful in predicting clot lysis (p = 0.001) and HT after thrombolysis (p = 0.017) with
sensitivity and specificity of 46% and 82%, respectively. S100B also predict final infarct volume
and eventually functional outcome (sensitivity 87%, specificity 78%).
Ye et al. [147] 2015
Meta-analysis (10 pooled
case-control studies enrolling
773 patients with IS and
438 healthy controls)
S100B IS diagnosis
Serum levels of S100B were higher in IS patients as compared to controls (SMD = 1.71
[95% CI 0.62–2.79]; p = 0.002). Subgroup analysis based on ethnicity revealed that S100B predict
IS progression in Asians but not in Caucasians. However, no statistical significance was observed
in large samples.
Kazmierski et al. [148] 2015 Prospective observational(458 IS patients) S100B HT
HT was associated with higher serum concentrations of S100B (AUC = 0.746; sensitivity 92.9%,
specificity 48.1%).
Tsai et al. [149] 2014 Case-control (100 IS patientsand 80 healthy subject) TBARS thiol 3-month NIHSS
As compared to controls, IS patients had higher TBARS and low free thiol. Furthermore, serum
levels of thiol were lower in large- than small-vessel disease. TBARS at day 7 was identified as
independent predictor of poor neurological outcome (OR 1.37 [95% CI 1.14–1.65]; p = 0.001).
Lorente et al. [150] 2015 Case-control (50 IS patientsand 100 healthy controls) MDA 30-day mortality
MDA levels were significantly higher in IS patients as compared to healthy controls, as well as in
non-surviving IS patients than in survivors (p < 0.001 for both). Furthermore, MDA predicted
30-day mortality (OR 7.23 [95% CI 1.84–28.73]; p = 0.005) with a sensitivity of 65% and a
specificity of 75% (AUC of 0.77).
Neuronal cell injury
Bharosay et al. [151] 2012 Case-control (150 IS patientsand 101 controls) NSE NIHSS at days 1–7
NSE was higher in IS patients (p < 0.001), also correlating with stroke severity at admission
(r = 0.919; p < 0.001) and after 7 days (r = 0.706; p < 0.001).
Singh et al. [152] 2013 Case-control (100 IS patientsand 101 controls) NSE NIHSS at admission Serum NSE was higher in IS group, also correlating with IS severity (r = 0.800; p < 0.001).
Zaheer et al. [153] 2013 Prospective observational(75 IS patients) NSE 30-day mRS
A positive correlation was found between NSE infarct size (r = 0.955, p < 0.001), whereas
a negative relationship with GCS was demonstrated (r = −0.806, p < 0.001). Finally, there was
a positive correlation between NSE and neurological outcome (r = 0.744, p < 0.001).
Kim et al. [155] 2014 Prospective observational(83 IS patients) NSE HT
In patients with HT, NSE time course was characterized by two peak levels. This specific pattern
was significantly associated with the occurrence of HT (OR 6.84 [95% CI 1.12–41.70]; p = 0.04).
Lu et al. [156] 2015 Prospective observational(74 IS patients) NSE 3-month mRS
NSE sowed predictive accuracy toward poor neurological outcome (77.1% sensitivity and
59.4% specificity). However, the adjusted RR for NSE was not effective in predicting poor
neurological outcome.
Haupt et al. [157] 2016 Prospective observational(31 IS patients) NSE mRS days 7 and 10
NSE peak at day 4 in the good outcome patients, whereas a continuous increase was observed
in those with poor outcome. Sensitivity of NSE analysis showing an increase over time to >90%
at day 4.
Park et al. [154] 2013 Case-control (111 IS patientsand 127 controls) H-FABP Stroke diagnosis
H-FABP was significantly higher in the IS group (OR 1.08 [95% CI 1.02–1.13]; p < 0.001). However,
H-FABP was not sensitive enough to discriminate stroke from control group or IS subtype.
HT: hemorrhagic transformation; IS: ischemic stroke; SMD: standardized mean differences; CI: confidence interval; AUC: area under the curve; TBARS: thiobarbituric acid-reactive
substances; OR: odds ratio; MDA: malonildyaldeide; NSE: neuron-specific enolase; NIHSS: National Institute of Health Stroke Scale; mRS: modified Rankin Scale; H-FABP: heart-type
fatty acid binding protein.
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Table 2. Non-specific inflammatory biomarkers potentially useful in stroke diagnosis, response to treatment, and outcome.
Author Year Study Design Biomarker Outcome Results
Ozkan et al. [158] 2013 Prospective observational(62 IS patients) CRP
Stroke subtype 3
months NIHSS CRP was unable to predict IS subtype and functional disability at 3 months after IS.
Taheraghdam et al. [159] 2013 Prospective observational(102 IS patients) CRP 3 months mRS Early CRP measurement failed to predict IS outcome.
VanGilder et al. [160] 2014 Systematic review(5 longitudinal/case-control studies) CRP 3 months mRS
In all studies, acutely elevated CRP was positively associated with long-term
(30 days to 3 months) unfavorable outcome (OR ranging from 2.3 to 3.5; p < 0.05).
Karlinski et al. [161] 2014 Prospective observational (301 ISpatients undergoing thrombolysis) CRP HT 3 months mRS
CRP measurement failed to independently predict the outcome of IS patients
treated with thrombolysis.
Pandey et al. [162] 2014 Case control (880 IS patients,32 HS and 50 healthy controls) CRP Day 7 NIHSS
CRP was significantly higher in stroke patients as compared to controls (p < 0.001
for both). When categorized on the basis of NIHSS, high serum levels of CRP were
found in severe stroke group (p < 0.001 for both).
Li et al. [163] 2015 Prospective observational(374 IS patients) PCT CRP 1-year mortality
Serum PCT levels were higher in non-survival patients (p < 0.001). Long-term
mortality was independently predicted by both PCT (OR 3.64 [95% CI 1.54–5.88])
and CRP (OR 12.33 [95% CI 2.44–37.66]). As compared to CRP, PCT was a better
predictor of mortality with a sensitivity of 81.5% and a specificity of 84.7%
(AUC 0.887).
Rocco et al. [164] 2015 Prospective observational(1242 IS patients) CRP 3 months mRS
Follow-up CRP, assessed during the first 7 days showed significant predictive value
toward worse mRS (OR 2.67 [95% CI 1.76–4.06]) and mortality
(OR 2.53 [95% CI 1.50–4.25]), with a c-statistic of 0.71 and 0.70, respectively.
Deng et al. [165] 2015 Case control(378 IS patients and 200 controls) PCT 3-month mRS
Serum PCT was higher in IS group and correlated with lesion size and NIHSS
(p < 0.001 for all). PCT predict worse functional outcome
(OR 3.45 [95% CI 2.29–4.77]; p < 0.001) with a sensitivity of 75.4% and a specificity
of 80.7% (AUC 0.845).
Wang et al. [166] 2016 Case-control(376 IS patients and 200 controls) PCT CRP
1-year mRS 1-year
mortality
Serum PCT was higher in patients with IS, and correlated with lesion size
(p < 0.001). Both PCT and CRP correlated with and NIHSS (p < 0.001 for both). PCT
predict worse functional outcome (OR 4.31 [95% CI 1.58–9.12]; p < 0.001). Mortality
was independently predicted by both PCT (OR 1.10 [95% CI 1.05–1.15]) and CRP
(OR 1.31 [95% CI 1.03–1.74]).
Matsuo et al. [167] 2016 Prospective observational(3653 IS patients) CRP 3 months mRS
At multivariate analysis, CRP was associated with a poor outcome
(OR 2.03 [95% CI 1.55–2.67]).
Geng et al. [168] 2016 Prospective observational(301 IS patients) CRP
Discharge mRS
Recurrent IS
At multivariate analysis, poor outcome at discharge was independently predicted
by CRP (OR 4.89 [95% CI 3.06–7.81]).
Whiteley et al. [169] 2009 Systematic review(4 longitudinal studies) IL-6 3-month mRS
Il-6 was identified as independent predictor of poor neurological outcome after IS
(OR 1.05 [1.01–1.09]).
Park et al. [170] 2013 Prospective observational(175 IS patients) IL-6 3-month mRS
In multivariate analysis IL-6 was independently associated with poor outcome
(OR 1.75 [1.25–2.25]; p = 0.001).
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Table 2. Cont.
Author Year Study Design Biomarker Outcome Results
Bustamante et al. [171] 2014
Meta-analysis
(24 pooled longitudinal studies
enrolling 4523 patients)
IL-6 1 to 6 months mRS
The highest quartile of IL-6 was an independent predictor of poor outcome
(OR 2.35 [1.81–3.03], p < 0.001), but its additional predictive value was modest in
terms of AUC (0.840 to 0.847).
Pusch et al. [172] 2015
Case-control study (76 patients with
IS, 44 with carotid stenosis and
66 with Parkinson disease)
IL-6 Post-IS infection
High concentration of IL-6, MCP-1, and S100B at 6 h, and increase of P-selectin
during the first 72 h were associated with post-stroke infections. Specifically, IL-6
predict the occurrence of post-stroke infection with an AUC of 0.920.
Lehmann et al. [173] 2015 Case-control study (95 patients withIS and 96 controls)
IL-6 CRP
MMP-9 Stroke subtype
As compared to controls, LAAS, LAC and CEI had higher serum levels of IL-6, CRP,
and MMP-9 (p < 0.05 for all).
Worthmann et al. [174] 2015 Prospective observational(56 IS patients)
IL-6 IL-10
CRP Post-IS infection
IL-10, IL-6 and CRP show a different time course in patients with and without
post-stroke infection. Furthermore, post-stroke infection is independently predicted
by serum IL-10 (AUC 0.76) and CRP (AUC 0.74).
Fahmi et al. [175] 2016 Case-control (50 IS patients and20 healthy controls) IL-6 15-day NIHSS
At multivariate regression analysis, IL-6 was identified as independent predictor of
short-tern neurological outcome (β = 0.451; p < 0.001).
Rodríguez-Yáñez et al. [176] 2013 Prospective observational(184 thrombolysed IS patients) IL-10 3-month mRS
High levels of IL-10 predicted good functional outcome with a specificity of 88%
and a sensibility of 86% (OR 2.86 [1.06–7.82]).
Ashour et al. [177] 2016 Case-control (60 IS patients and30 healthy control) IL-10 Post-IS infection
The occurrence of infectious was independently predicted by increased levels of
IL-10 (OR 6.01 [1.53–23.51]; p = 0.01).
Inzitari et al. [179] 2013 Prospective observational(327 thrombolysed IS patients) MMP-9
HT 3-months death
3-month mRS
Overtime MMP-9 variations (during 24 h across thrombolysis) significantly
predicted HT (OR 1.40 [1.02–1.92]) and death (OR 1.58 [1.11–2.26]).
Carbone et al. [178] 2015 Case-control (60 thrombolysedIS patients and 30 not) MMP-9 HT
Peak of MMP-9 (and also MMP-8 and MPO) at day 1 in thrombolysed patients was
associated with increased rate of early HT (p = 0.023).
IS: ischemic stroke; NIHSS: National Institute of Health Stroke Scale; CRP: C-reactive protein; mRS: modified Rankin Scale; OR: odds ratio; HT: hemorrhagic transformation; PCT:
procalcitonin; CI: confidence interval; AUC: area under the curve; IL: interleukin; MMP-9: matrix metalloproteinase; LAAS: large artery atherosclerotic stroke; LAC: lacunar stroke;
CEI: cardio-embolic stroke; MPO: myeloperoxidase.
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Table 3. Vascular biomarkers potentially useful in stroke diagnosis, response to treatment, and outcome.
Author Year Study Design Biomarker Outcome Results
Wiseman et al. [180] 2014
Meta-analysis (42 pooled case-control







As compared to other subtypes, lacunar IS was characterized by higher markers
of coagulation/fibrinolysis (t-PA, PAI-1, and D-dimer) and lower marker of
endothelial dysfunction (vWF, E- and P-selectins, ICAM-1 and VCAM-1).
Liu et al. [181] 2016 Case-control(317 IS of different subtypes) D-dimer Stroke subtype
D-dimer was different in each group with the highest levels in the CE group
(<0.001). D-dimer also independently predicted CE (OR 6.83 [95% CI 2.96–15.77]).
Yuan et al. [182] 2014 Prospective observational(300 IS patients) D-dimer
Stroke subtype
Day 14 NIHSS
Serum levels of D-dimer were higher in the CE group; Furthermore they
correlated with neurological improvement (r = −0.410; p = 0.013).
Yang et al. [183] 2014 Prospective observational(220 IS patients) D-dimer
3-month mRS
3-month mortality
Admission D-dimer was higher in patients with poor prognosis also in adjusted
analysis (OR 2.18 [95% CI 1.55–2.83]) with high prognostic accuracy (AUC: 0.830).
D-dimer also predicted mortality analysis (OR 3.22 [95% CI 2.05–6.43]).
Richard et al. [184] 2015 Prospective observational(100 IS patients)
E-, P-selectin ICAM-1
VCAM-1 3-month mRS
Early after SI, E-selectin was found to be an independent predictor of poor
outcome (OR = 24.95 [95% CI 2–354]; p = 0.022 and AUC = 0.780), as was VCAM-1
during the third week after onset (OR = 8 [95% CI 2–37]; p = 0.01 and AUC 0.730).
Wang et al. [185] 2016 Case-control (1173 IS patients) D-dimer 30-day mRS D-dimer was effective in predicting poor neurological score(OR = 1.60 [95% CI 1.36–1.89]; p < 0.001).
Hsu et al. [186] 2016 Retrospective observational(307 thrombolysed IS patients) D-dimer 3-month mRS HT
At adjusted analysis, higher levels of D-dimer at admission predicted poor
outcome (OR = 1.90 [95% CI 1.27–2.86]; p = 0.002) and HT
(OR = 2.97 [95% CI 1.15–7.70]; p = 0.025).
t-PA: tissue-type plasminogen activator; PAI: plasminogen activator inhibitor; vWF: Von Willebrand factor; ICAM: intracellular adhesion molecule; VCAM: vascular cell adhesion
molecule; CE: cardio-embolic; OR: odds ratio; CI: confidence interval; IS: ischemic stroke; NIHSS: National Institute of Health Stroke Scale; mRS: modified Rankin Scale; AUC: area
under the curve; ADMA: asymmetric dimethylarginine; HT: hemorrhagic transformation.
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Inflammatory molecules secreted by NVU may be released in the bloodstream, thus activating the
immune system. Therefore, also systemic inflammatory mediators may contribute to IS diagnosis and
risk stratification (Table 2). Increased C-reactive protein (CRP) concentration represents a well-known
predictor of first/recurrent cerebrovascular events [168,194], but whether it also serves as a prognostic
factor has not yet been established. Early increase of CRP occurs in IS and in many other inflammatory
conditions as well, thus reflecting the low specificity of this biomarker. Furthermore, various
studies suggested a potential role of CRP as predictor of worse neurological outcome, but this
evidence remains controversial [158–164,167,168,195]. In this regard, a recent systematic review
from 46 studies recognized CRP as independent predictor of long-term functional outcome in only
13 studies [196]. The high variability in the study design and the lack of classification/discrimination
over clinical variables further challenge the clinical use of CRP, at least as single biomarker.
Noteworthy, procalcitonin showed better accuracy in predicting 1-year mortality after IS as compared
to CRP [163,166]. As this association was confirmed even after adjusting for stroke severity, it seems
that procalcitonin may provide additional general prognostic information. Indeed, procalcitonin
was demonstrated to correlate with IS severity at admission as well as to predict worse long-term
neurological outcome [165,166]. Similarly, the predictive value of cytokine release remains to be
fully understood. Up-regulation of TNF-α, IL-1β, IL-6, and IL-10 has been largely investigated in
experimental studies, whereas over time variations in human serum have been described in several
cohorts. However, data on peripheral cytokine release are extremely variable, likely due to the
difference in IS severity, location, age, co-morbidities, and systemic inflammatory status at admission.
Furthermore, this variability is of paramount importance in case-control study design [197]. According
to those limitations, IL-6 has been suggested as promising biomarker of short- and long-term worse
neurological outcome in different studies [169,170,175]. However, a recent meta-analysis pooling
24 longitudinal studies emphasized the low prognostic accuracy of IL-6 [171]. Interestingly, IL-6
has also been shown to predict the occurrence of infection in patients suffering from an IS [172,174].
Conversely, the anti-inflammatory cytokine IL-10 showed a different time course, characterized by
a delayed increase over 72 h post-IS [198]. Consistent with experimental evidence, high levels of IL-10
has been recently associated to good functional outcome [176], but also an increased risk of post-IS
infections has been described [177]. Despite those promising evidence, the assay of single inflammatory
mediator does not reflect the heterogeneity and complexity of systemic immune response. Rather,
development of panels including different biomarkers might be more representative and then useful
for clinical practice. Furthermore, few studies have assessed the time line of cytokine release and how
their balance affects neurological outcome. Understanding this balance might be critical for better
defining the time window for cytokine assay.
Only recently the impact of neutrophil degranulation has been investigated [199]. Inzitari and
co-workers first indicated the pre- and post-thrombolysis variations of serum MMP-9 as predictor
of HT and worse long-term outcome, defined as death and poor modified Rankin scale score [179].
More recently, our research group confirmed the neutrophil burst induced by thrombolysis, also linking
the neutrophil release of MMP-9, MMP-8, and myeloperoxidase (MPO) to the occurrence of HT in the
first day after IS [178].
As athero-thrombotic disease, both coagulation/fibrinolysis cascade and endothelial dysfunction
contribute to IS pathophysiology [180]. Especially D-dimer was effective in identifying IS
etiology [181,182] and showed good prognostic accuracy as predictor of short- and long-term worse
outcome [182,183,185,186]. Similar results were also reported for E-selectin and VCAM-1, but those
data required further validation in additional large-cohort studies [184].
4.2. New Candidate Inflammatory Biomarkers
The release of endogenous alarmins—also referred to as DAMPs—from necrotic cerebral cells
has been indicated as early promoter of local and systemic inflammatory cascade [200]. Among
them, several studies in the last years investigated the HMGB1 in human stroke patients as
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a pro-inflammatory biomarker (Table 4) [132,201–205]. Persistent increase of serum HMGB1 occurs
early after IS and lasts over 30 days. HMGB1 correlates with circulating leukocytes and promotes the
release of inflammatory mediators [206,207].
Similarly, adipocytokines recently emerged as inflammatory mediators potentially associated
with the risk of stroke [208,209], but whether they have a role in stroke pathophysiology has not
yet been established. In two studies, APN failed to predict long-term outcome, but was shown to
correlated with IS etiology and short-term neurological disability [204,205]. Instead, our research
group highlighted the potential role of leptin/APN ratio as potential strategy for prediction of early
HT and long-term worse outcome [132].
Table 4. New candidate inflammatory biomarkers potentially useful in stroke diagnosis, response to
treatment, and outcome.
Author Year Study Design Biomarker Outcome Results





Plasma HMGB1 weakly correlated with
infarct volume and stroke severity at day 3
after IS. However, HMGB1 failed to
independently predict long-term outcome.





HMGB1 was independently associate with
worse clinical outcome (OR 2.21
[95% CI 1.13–4.20]; p = 0.002) with 71.4%
sensitivity and 83.7% specificity (AUC,
0.83). Furthermore, in a combined model,
HMGB1 significantly improved the AUC
of NIHSS score to 0.929 (p < 0.001).






The increased HMGB1 levels and plasma
MMP-9 are associated with a poor
functional outcome and significantly
correlated with each other (p < 0.05).




Adiponectin mRS at 1 and6 months
Higher Adiponectin was indicative
worse outcome on month 1 (OR = 1.14
[95% CI 1.01–1.29]; p = 0.031). However,
adiponectin failed to predict IS severity,
infarct size, recurrent IS, mortality, state,
disability or functional outcome at
6 months.






As compared to controls, average
adiponectin values at onset were
significantly lower and higher in patients
with ATBI (p = 0.047) and CE (p = 0.008) IS,
respectively. At onset adiponectin
correlated with NIHSS (r = 0.420, p = 0.003)
and was higher in patients with worse
long-term outcome (p = 0.007).







Serum leptin and leptin/adiponectin ratio
at day 1 inversely correlated with both
radiological and clinical parameters.
Leptin/adiponectin ratio also
independently predicted worse
neurological outcome (OR = 0.15
[95% CI 0.03–0.83]; p = 0.030) and the
occurrence of HT (OR = 0.08
[95% CI 0.01–0.81]; p = 0.028).
mRS: modified Rankin Scale; HMGB1: high-mobility group box-1; IS: ischemic stroke; OR: odds ratio;
CI: confidence interval; AUC: area under the curve; NIHSS: National Institute of Health Stroke Scale; GOS:
Glasgow outcome scale; MMP: matrix metalloproteinase; ATBI: atherothrombotic stroke; CE: cardio-embolic;
HT: hemorrhagic transformation.
5. Anti-Inflammatory Treatments in IS: Evidence from Pre-Clinical Studies
As inflammatory and immune-mediated mechanisms of neuronal injury have received greater
attention, many drugs have been developed or tested if used in other settings (Figure 5). Several
treatments modulating inflammatory and immune responses to brain ischemia have entered
pre-clinical trials with different and sometimes contrasting results (Table 5) [10,210–253].
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cluster of differentiation; COX: cyclooxygenase; IL: interleukin; O2−: superoxyde ion; TNF: tumor 
necrosis factor; Ra: receptor agonist. 
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IL-1 has been shown to play a central role in brain injury since long time. Beneficial effects of 
IL-1Ra in stroke are not fully cleared, but existing data suggest neuroprotective and 
vasculoprotective effects. In particular, neuroprotective effects are greater after co-administration 
with excitotoxins in the rat brain, whilst vasculoprotective effects are mainly linked to the 
prevention of BBB impairment and the blocking of neutrophil migration [254]. 
Treatment with recombinant IL-1Ra in rats with permanent middle cerebral artery occlusion 
(MCAO) was described to be protective, both after central and peripheral administration [255,256]. 
In a temporary MCAO model of rats, the intra-cerebroventricular injection of the anti-IL-1β antibody 
was also found to limit the ischemic injury [247]. Interestingly, delayed administration of IL-1Ra in 
rats was noted to reduce infarct volume after permanent MCAO, as peripheral administration did, 
too [236,257]. Transgenic mice further increased the evidence of an essential role for IL-1 in stroke; in 
fact, the genetic deletion of IL-1α and IL-1β in rodents assured a marked reduction in lesion volume 
during brain ischemia in experimental stroke [258]. The first meta-analysis and systematic review on 
IL-1Ra effectiveness in IS dates back to 2009, confirming protective effects and underscoring the lack 
of studies using systemic administration, delayed treatment, and animals with important 
comorbidities [259]. These concerns were addressed and IL-1Ra after delayed subcutaneous 
administration in corpulent rats confirmed its efficacy [234]. Apart from corpulent rats, those with 
pneumonia or treated with LPS and aged animals were tested, but these comorbidities did not alter 
the heterogeneity, the efficacy of IL-1Ra being maintained; nevertheless, the efficacy must still be 
tested in animals with hypertension and other than rodents [260]. IL-1Ra was also demonstrated to 
enter the brain parenchyma at therapeutic doses after systemic administration both after transient 
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tested in animals with hypertension and other than rodents [260]. IL-1Ra was also demonstrated to
enter the brain parenchyma at therapeutic doses after systemic administration both after transient and
permanent MCAO in rats, providing long-term functional recovery [234]. Interestingly, IL-1Ra was
recently confirmed to maintain its protective effects for more than 20 years [261]. Finally, three phase II
randomized clinical trials (RCTs) have been completed, one is still ongoing, and another is planned to
start in 2018; no phase III trials are currently under development. The two completed studies showed
it is well tolerated and no safety concerns were highlighted [261,262]. Current phase II trials in the
United Kingdom are investigating subcutaneous IL-1Ra, which maintained its efficacy [260].
5.2. Statins
Since long time, statins were demonstrated to exert neuro-protective effects on ischemic brain
by the selective up-regulation of eNOS. Prophylactic therapy with statins increased cerebral blood
flow, reduced infarct size, and enhanced clinical outcomes in normocholesterolemic mice. The blood
flow and neuroprotective effects of statins did not take place in eNOS-deficient mice, indicating
that improved eNOS activity by statins represents the main mechanism of neuroprotection [219].
In stroke-prone spontaneously hypertensive rats chronically treated with cerivastatin, the incidence
and the size of stroke were significantly reduced as well as stroke-associated symptoms and
early mortality; interestingly, statin treatment significantly decreased superoxide production from
non-stroke parenchyma of brain and infiltration of inflammatory cells to injured tissues, confirming the
neuroprotective effects of this drug class [222]. These findings were confirmed also with mevastatin
and rosuvastatin upregulating eNOS and enhancing cerebral blood flow [211,235,263]. Moreover,
in a mouse model of embolic focal ischemia after long-term (14 days) simvastatin, atorvastatin or
vehicle treatment, ischemic lesion volume and neurologic deficits were significantly decreased by
both simvastatin and atorvastatin, which increased eNOS and tissue-type plasminogen activator
(t-PA) mRNA levels without changes in mRNA levels of plasminogen activator inhibitor-1. While in
eNOS knockout mice atorvastatin was shown to reduce the volume of ischemic injury and enhance
neurologic outcomes after arterial embolic occlusion, statins were not protective in t-PA knockout
mice, confirming the beneficial effects of statins in IS by both eNOS and t-PA [212]. Atorvastatin
and simvastatin were described to enhance functional outcomes and brain plasticity in IS rats [215].
In particular, atorvastatin treatment exhibited significant increases in vascular endothelial growth
factor, cyclic guanosine monophosphate, synaptophysin and stimulated angiogenesis, endogenous cell
proliferation, and neurogenesis, indicating an essential role for atorvastatin in inducing post-stroke
brain plasticity. Treatment with simvastatin in rats after MCAO blocked the increase in brain infarct
volume after 24 h and induced a consistent reduction after 48 h; the same beneficial effect was observed
when simvastatin was administered before the induction of focal ischemia and confirmed by magnetic
resonance imaging (MRI). The neuroprotective effects of simvastatin were coupled to an increase
in eNOS immunoreactivity found in simvastatin-treated rat brain [242]. In simvastatin-pre-treated
cultured human brain microvascular endothelial cells (BMECs) then subjected to oxygen glucose
deprivation (OGD), the expression of MMP-2 was reduced, whilst MMP-9 synthesis rate was low
and unaffected by simvastatin treatment. Tissue inhibitor metalloproteinase (TIMP)-1 and TIMP-2
gene expression and protein secretion were both strongly induced, demonstrating the positive effect
of simvastatin on MMP metabolism in human BMECs and experimental stroke [238]. A systematic
review and meta-analysis by Baryan and co-workers confirmed the neuroprotective effects of statins in
animal post-stroke recovery in terms of both reduction of infarct size and improvement of neurological
outcome [264]. A more recent meta-analysis involving non-industry-sponsored preclinical studies
confirmed the previous data, showing that the effect of statins was significantly larger for studies
sponsored by non-industry sources than studies sponsored by industry [265].
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Table 5. Anti-inflammatory treatments in ischemic stroke: evidence from preclinical studies.
Study Year Treatment Sample Size Outcome
IL-1Ra
Garcia et al. [256] 1995
13 with pMCAO and treated with IL-1Ra;
13 with pMCAO and treated with CSE buffer
or placebo group (n = 13); 2 sham-operated
animals treated with IL-1Ra or CSE (n = 2)
30 outbred male Wistar rats and
fed Agway rat chow during the
4–6 quarantine days
IL-1Ra in rats with pMCAO significantly decreased the number
of necrotic neurons both at 24 h and 7 days after the arterial
occlusion (p < 0.0001). Neurological scores were also significantly
improved with and a non-significant decrease in the number of
PMN leukocytes in the ischemic hemisphere was observed.
Yamasaki et al. [247] 1995 60 min of tMCAO followed by reperfusion;first IL-1β, then anti-IL1β was injected 120 adult male Wistar rats
tMCAO induced an increase in brain water content, necrosis,
and neutrophilic infiltration in the cortex perfused by the MCA
and the DCP and VCP. rIL-1β into the left lateral ventricle
immediately after reperfusion markedly enhanced ischemic brain
edema formation and infarction size in MCA zone, DCP, and VCP
in a dose-dependent manner (p < 0.01). Anti-IL-1β attenuated the
post-ischemic increase of brain water content and decreased the
infarction size (p < 0.01). The number of neutrophils infiltrating
the ischemic area decreased with anti-IL-1β.
Relton et al. [236] 1996
MCAO or sham surgery. Animals were
injected subcutaneously with either vehicle or
rIL-1Ra at 0, 4, 8, 12, and 18 h after ischemia.
In separate experiments, initial treatment was
delayed until 30 min, 1 h, or 4 h after ischemia
and treatments were repeated until 18 h
Male Sprague-Dawley rats
rIL-1Ra significantly inhibited infarct size by 46% at 24 h
(p < 0.05), cerebral edema formation by 49% at 24 h (p < 0.05).
Infarction inhibition by rIL-1Ra was dependent on dose and
time of administration.
Pradillo et al. [234] 2012
Lean and Cp rats received placebo or IL-1Ra
(25 and 12.5 mg/kg) subcutaneously at
reperfusion and 6 h later and allocated to
different groups: lean + tMCAO + placebo;
lean + tMCAO + IL-1Ra; Cp + tMCAO +
placebo; and Cp + tMCAO + IL-1Ra. For the
delayed administration study, animals were
injected subcutaneously with placebo or
IL-1Ra at 3 h of reperfusion and again 3 h later
Male, lean and Cp rats
IL-1Ra at reperfusion resulted in a 50% reduction of infarct
volume as measured by MRI both in lean and Cp compared with
placebo-treated animals (p < 0.05). IL-1Ra decreased the number
of MMP-9-positive neutrophils when compared with placebo
(p < 0.05). In both lean and Cp rats, IL-1Ra largely reduced the
microglial activation compared with the placebo-treated groups
(p < 0.05). In 16-month-old lean rats, delayed IL-1Ra significantly
reduced the number of MMP-9-positive blood vessels and the
number of MMP-9-positive neutrophils when compared with the
placebo group (p < 0.05).
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Study Year Treatment Sample Size Outcome
Statins
Endres et al. [219] 1998
After tMCAO followed by reperfusion,
mice were injected subcutaneously with
0.1 mL of activated simvastatin or lovastatin
(0.2–20 mg/kg) or a corresponding volume
of PBS once daily for 3 or 14 days
Not declared
In a concentration-dependent manner, simvastatin for 14 days
reduced cerebral infarct size by 18, 27 and 46% (p < 0.05) and
increased NOS activity (p < 0.05). Simvastatin 20 mg/kg
increased basal hemispheric CBF by 31% (p < 0.05). Lovastatin
20 mg/kg daily for 14 days also decreased cerebral infarct size and
neurological deficits, even if to a lesser extent than simvastatin.
Kawashima et al. [222] 2003
Two groups, one statin-treated (cerivastatin




(4 weeks of age)
The incidence of stroke and stroke size decreased (p < 0.01).
High-dose statin treatment delayed early death and reduced the
occurrence of stroke-associated symptoms (p < 0.01) and
decreased stroke-associated infiltration of inflammatory cells
(p < 0.05). Statin treatment increased eNOS protein levels and
eNOS activity (p < 0.05). Superoxide production was reduced
in statin-treated rats (p < 0.01).
Amin-Hanjani et al. [211] 2001
Two groups: mevastatin at a dose of 2 or
20 mg/kg daily and a corresponding
concentration of vehicle for 7, 14, or 28 days
before tMCAO
Wild-type male mice and
eNOS-deficient male mice
Mevastatin increased levels of eNOS mRNA and protein, reduced
infarct size, and improved neurological deficits in a dose- and
time-dependent manner especially with 14- and 28-day high-dose
treatment (26% and 37% infarct reduction, respectively, p < 0.05).
Cholesterol levels were reduced only after 28 days of treatment
(p < 0.05), but did not correlate with infarct reduction. Baseline
absolute cerebral blood flow was 30% higher after 14-day
high-dose treatment (p < 0.05).
Prinz et al. [235] 2008
After tMCAO followed by reperfusion, mice
were treated with intravenously or
intraperitoneally rosuvastatin given up to
6 h after MCAO (0.02–20 mg/kg)
Wild-type mice aged 6 to
8 weeks
Intravenous rosuvastatin significantly reduced lesion size up to
4 h after MCAO in doses as low as 0.2 mg/kg (p < 0.05).
Intraperitoneal administration provided protection only on
reperfusion at a dose of 20 mg/kg (p < 0.05). Lesion protection
was evident 5 days after brain ischemia and was associated with
functional improvements at 2.0 mg/kg dose (p < 0.05).
Neuroprotection with intravenous rosuvastatin was achieved
with peak plasma concentrations <0.5 ng/mL and was associated
with increased levels of phosphorylated Akt kinase and eNOS in
the vasculature (p < 0.05).
Int. J. Mol. Sci. 2016, 17, 1967 22 of 53
Table 5. Cont.
Study Year Treatment Sample Size Outcome
Asahi et al. [212] 2005
Heterologous blood clots were used to
induce MCAO after long-term simvastatin
(20 mg/kg), atorvastatin (20 mg/kg) or vehicle
treatment subcutaneously
Male SV-129 mice and male
C57Bl/6 mice
In wild-type mice, both simvastatin and atorvastatin reduced
ischemic lesions and residual clot after 14 days (p < 0.05).
In eNOS knockout mice, atorvastatin reduced the volume of
ischemic tissue and improved neurologic outcomes after arterial
occlusion (p < 0.05). Both statins did not have protective effects in
t-PA knockout mice after embolic focal ischemia, but only in
a filament model where focal ischemia was achieved via
mechanical occlusion (p < 0.05).
Chen et al. [215] 2003
24 h after MCAO, rats were fed atorvastatin
(1, 3 or 8 mg/kg) daily for 7 days. Rats were
also treated with simvastatin 1 mg/kg with the
same protocol
48 Adult male Wistar rats
Rats treated with 1 and 3 mg/kg atorvastatin and 1 mg/kg
simvastatin improved functional recovery (p < 0.05). VEGF
production within the ischemic boundary area at 14 days after
stroke increased in the 1 mg/kg atorvastatin group (p < 0.05) as
well as cyclic guanosine monophosphate, angiogenesis,
neurogenesis, and synaptophysin levels (p < 0.05).
Sironi et al. [242] 2003
Two groups of rats were treated with vehicle
alone or simvastatin for 3 days before MCAO,
while other two groups underwent MCAO and
were treated with vehicle or simvastatin at
3 and 25 h after the induction of the injury. The
brain infarct size was evaluated using MRI
Male Sprague-Dawley rats
Treatment with simvastatin (20 mg/kg) after MCAO prevented
the increase in brain infarct volume occurring at 24 h and induced
a 46.6% reduction after 48 h (p < 0.01). The neuroprotective effects
of simvastatin were paralleled by an increase in eNOS
immunoreactivity, detectable in the brain of
simvastatin-treated rats.
Reuter et al. [238] 2015 Cultured hBMECs pretreated with simvastatinand subjected to OGD hBMECs
Simvastatin significantly blocked the expression of MMP-2 under
OGD (p < 0.004). MMP-9 synthesis rate was low and unaffected
by simvastatin treatment, while the gene expression and protein
secretion of TIMP-1 and TIMP-2 were both strongly induced
(p < 0.001).
Fingolimod (FTY720)
Rolland et al. [239] 2013
Fingolimod was given intraperitoneally at a
dose of 1 mg/kg as single dose 1 h after ICH
induction or daily administration 1, 24, and
48 h after ICH induction
103 male CD-1 mice and
28 male Sprague-Dawley rats
Fingolimod enhanced neurological functions and reduced brain
edema at 24 and 72 h following experimental ICH in CD-1 mice
(p < 0.05). Fewer lymphocytes were found in blood and brain
samples of treated animals (p < 0.05). Fingolimod decreased
ICAM-1, IFN-γ, IL-17 levels 72 h after ICH (p < 0.05). Treated
Sprague-Dawley rats showed less spatial and motor learning
deficits along with significantly reduced brain atrophy and
neuronal cell loss within the basal ganglia (p < 0.05).
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Campos et al. [214] 2013
3 cohorts: pMCAO not treated with t-PA;
tMCAO followed by early (30 min after
thrombin) t-PA administration; and tMCAO
followed by delayed (3 h after thrombin) t-PA
administration. Each of these cohort received
fingolimod at different time points
C57BL/6 male mice
Fingolimod reduced neurological deficits and infarct volume
after in situ thromboembolic MCAO (p < 0.05). Combination of
fingolimod and t-PA improved neurological outcomes of the
thrombolytic therapy and the risk of hemorrhagic transformation
associated with delayed administration of t-PA (p < 0.05).
Donepezil
Wang et al. [244] 2014
3 groups: the sham operation group (SO), the
model group (MG) and the treatment group
(TG). Pathological appearance of the
hippocampal CA1 region and calpain I and
CDK5/p25 expression were observed on the
4th, 6th and 8th week from I/R surgery
250 3-month old male mice
At each postoperative time point, the normal neuron count of the
hippocampal CA1 region in the treatment group increased
significantly (p < 0.05), whereas calpain I and CDK5/p25
expression, SOD activity and MDA content were significantly
lower than those in the model group (p < 0.05).
Min et al. [231] 2012
After transient global ischemia, donepezil
(5 mg/kg once a day) was administered
intragastrically for 21 days
Male Mongolian gerbils
Donepezil significantly inhibited delayed neuronal death in the
hippocampal CA1 region (p < 0.01). Memory impairment was
significantly improved by donepezil treatment (p < 0.05–0.01).
Western blot analysis showed that donepezil treatment prevented
reductions in p-CaMKII and p-CREB protein levels in the
hippocampus (p < 0.01).
Yuan et al. [252] 2011 Cultured cells were exposed to both OGD andelectrophysiological experiment
HEK293 cells from a human
embryonic kidney cell line
Donepezil showed to attenuate OGD-induced apoptosis in
Kv2.1/HEK293 cells and to inhibit Kv2.1 currents in a
dose-dependent manner under normoxic condition (p < 0.01).
Donepezil further inhibited Kv2.1 currents after OGD
treatment (p < 0.05).
Akasofu et al. [210] 2008
Prolonged opening of sodium channels with
veratridine led to depolarization-induced
neuronal cell injury, which was prevented by
0.1 µM tetrodotoxin
Cortical cell cultures from fetal
rats of the Wistar strain
Pre-treatment with donepezil (0.1–10 µM) for 1 day significantly
decreased cell death and increased cell viability in a
concentration-dependent manner (p < 0.05). At 0.1–10 µM,
donepezil concentration-dependently decreased the
veratridine-induced increase of calcium concentration, whilst at
10 µM it reduced the veratridine-induced increase of sodium
concentration (p < 0.05 for both).
Lee et al. [225] 2007
After permanent ligation of bilateral common
carotid arteries, rats were administered
cilostazol (30 mg/kg/day orally) and
donepezil (0.3 mg/kg/day intraperitoneally)
Rats
Concurrent treatment with cilostazol and donepezil prevented
neuropathological alterations in the white matter by activation of
phosphorylated CREB and Bcl-2, resulting in improvement of
spatial learning memory (p < 0.05).
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Citalopram
Espinera et al. [220] 2013
After focal ischemic stroke, citalopram
10 mg/kg was injected intraperitoneally
24 h after stroke and then daily for 7, 14, 21,
or 28 days
Adult male C57 mice
Citalopram had no significant effect on infarct formation or
edema 3 days after stroke, but enhanced sensorimotor functional
recovery after 14 days (p < 0.05). Citalopram improved
neuroblast proliferation and migration (p < 0.01) as well as
neurogenesis (p < 0.05) and peri-infarction vessel density
(p < 0.05) in the post-ischemic brain.
Kronenberg et al. [223] 2012
Mice were subjected to 30-min
MCAO/reperfusion and serial MRI scans;
a subset of animals received citalopram from
day 7 after MCAO
Male 129/SV mice
Delayed citalopram reversed the behavioral phenotype blocked
the degeneration of dopaminergic midbrain neurons, and
attenuated striatal atrophy after 4 months (p < 0.05).
Natalizumab
Becker et al. [213] 2001
Rats underwent 3 h of MCAO followed by 45 h
of reperfusion. 2 h after ischemia, one group
received anti-α4 integrin antibody
intraperitoneally and another an isotype
control antibody
Male Lewis rats
Neurological deficits were less frequent in treated rats at 24
(p < 0.01) and 48 h (p = 0.01) after ischemia. White blood cell
count was higher in treated rats (p < 0.01) with a
lymphocyte/monocyte predominance. Infarction volume was
reduced in treated animals (p = 0.012).
Relton et al. [237] 2001
Rats underwent 1-h MCAO followed by 23-h
reperfusion. 24 h before MCAO were injected
intravenously with anti-α4 integrin antibody




Treated animals showed reduced total infarct volume
(p < 0.05–0.01). Moreover, treatment reduced brain
myeloperoxidase activity (p < 0.05). No significant difference in
white blood cell count was observed. Leukocyte counts were
elevated in TA-2-treated rats.
Liesz et al. [226] 2011
24 h before or 3 h after ischemia, mice were
administered 300 mg of CD49d-specific
monoclonal antibody intraperitoneally after;
control animals received rat IgG2b isotype
control monoclonal antibody
Male mice C57BL/6J aged
10–12 weeks
VLA-4 blockade improved outcome after 7 days from MCAO via
the inhibition of cerebral leukocyte invasion and neurotoxic
cytokine production (p < 0.01). VLA-4 inhibition reduced the
post-ischemic VCAM-1 up-regulation (p < 0.01).
Langhauser et al. [224] 2014
24 h before or 3 h after cerebral ischemia (both
tMCAO and pMCAO), mice were treated with
300 µg of a monoclonal antibody anti-CD49d
Male C57Bl/6 mice
VLA-4 blocking reduced T cell and neutrophil invasion after
5 days following MCAO and inhibited the up-regulation of
VCAM-1 (p < 0.05). Anti-CD49d antibody could not influence
stroke outcome positively, irrespective of the model or the time
point investigated.
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Study Year Treatment Sample Size Outcome
Neumann et al. [232] 2015
After focal cerebral ischemia was induced by
pMCAO, anti-CD49d treatment was
administered intravenously
LysM-eGFP mice
The systemic blockade of VLA-4 resulted in reduction of
adherence of neutrophils (p < 0.05) and inhibition of their
infiltration (p < 0.01) 24 h after focal ischemia. Moreover,
anti-VLA-4 treatment improved neurological outcome and
reduced infarct volume at day 3 after stroke (p < 0.05).
Llovera et al. [230] 2015
After cMCAO (for small lesions confined to the
cortex) or fMCAO (for lesions in the cortex and
subcortical structures) was assessed,
anti-CD49d treatment was administered
intraperitoneally 3 h after stroke induction
315 male C57BL/6J mice
Anti-CD49d treatment reduced infarct volume (p < 0.05) and
leukocytes invasion into the ischemic brain (p < 0.001) after
7 days from cMCAO (p < 0.05). After fMCAO, mice had fewer
cerebral leukocytes than after cMCAO (p < 0.001), but anti-CD49d
treatment did not affect leukocyte invasion after fMCAO.
Cyclosporine A
Uchino et al. [243] 1998
CsA was given intraperitoneally daily for
1 week before and 1 week after forebrain
ischemia of 7 or 10 min duration
Rats
Systemically administered CsA ameliorated the damage to the
CA1 sector of the hippocampus due to transient ischemia
(p < 0.001).
Cho et al. [217] 2013
Rats underwent MCAO and then randomly
treated by intracarotid CsA 10 mg/kg 20 min
before MCAO (pre-treatment group);
intracarotid CsA 10 mg/kg immediately after
reperfusion (post-treatment); and intracarotid
saline immediately after reperfusion
27 Sprague-Dawley rats
On day 1, a significant reduction of infarct size in the
pre-treatment group compared to the post-treatment (p < 0.004)
was evaluated. A significant reduction of microglial cell count in
the pre-treatment group compared to either saline or
post-treatment groups was found (p < 0.001).
Yu et al. [250] 2004
Rats underwent MCAO then were randomly
treated with either: low dose CsA, MP, low
dose CsA plus MP, high dose CsA, or vehicle
Adult Sprague-Dawley rats
Animals receiving high dose CsA alone exhibited a minor motor
asymmetry and less neurologic deficits 3 days after stroke
(p < 0.0001) as well as those receiving low dose CsA and MP
treatment but only on day 1 post-stroke (p <0.005). Animals
receiving high dose CsA alone exhibited significantly (p < 0.0001).
Yuen et al. [253] 2011
Rats were equally divided into sham
control, intraperitoneal physiological saline
(at 0.5/24/48 h after stroke), CsA (20 mg/kg at
0.5/24 h intraperitoneally), EPO (5000 IU/kg
at 0.5/24/48 h, subcutaneously), combined




On day 21, improvement in neurological function was found in
CsA and EPO group (p < 0.05) and was higher when the
combined treatment was administered (p < 0.004). Attenuation of
inflammatory response, apoptosis, and oxidative stress was
found with combined therapy with CsA and EPO (p < 0.05).
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Edaravone
Fujiwara et al. [221] 2016
Before 90-min MCAO followed by reperfusion,
rats were randomly assigned to intravenous
vehicle or intravenous edaravone 3 mg/kg
Male Sprague-Dawley rats
Edaravone decreased infarct volume and edema formation and
IL-1β and MMP-9 levels 3 h after ischemia levels (p < 0.05).
Edaravone was shown to reduce levels of many other
pro-inflammatory cytokines.
Yamashita et al. [248] 2015
Thrombolysis was evaluated by using a
He-Ne-laser-induced thrombosis model in
mesenteric microvessels. 3 experimental
groups (placebo, alteplase 0.6 mg/kg, alteplase
0.6 mg/kg + edaravone 10.5 mg/kg)
Male Wistar–ST rats
In the alteplase group, thrombus volume decreased (p < 0.01)
after 20 min. In the alteplase+edaravone group, thrombus
volume was more evident (p < 0.001).
Wu et al. [245] 2014
Rats were subjected to tMCAO and then
administered edaravone 2.4 mg/kg; a subset of
these animals were administered both
edaravone 2.4 mg/kg and borneol 0.6 mg/kg
Sprague-Dawley rats
Edaravone was demonstrated to scavenge free radicals.
Edavarone and borneol reduced the infarct area (p < 0.001) and
the effect was increased when drugs were administered
synergistically (p < 0.001).
IL-1Ra: interleukin-1 receptor antagonist; pMCAO: permanent middle cerebral artery occlusion; CV: cardiovascular; PMN: polymorphonuclear; tMCAO: transient middle cerebral
artery occlusion; DCP: dorsal area of caudate putamen; VCP: ventral area of the caudate putamen; rIL-1β: recombinant interleukin-1β; MRI: magnetic resonance imaging; MMP:
metalloproteinase; CBF: cerebral blood flow; eNOS: endothelial nitric oxide synthase; t-PA: tissue-type plasminogen activator; VEGF: vascular endothelial growth factor; hBMEC:
human brain microvascular endothelial cells; OGD: oxygen glucose deprivation; ICH: intracerebral hemorrhage; ICAM-1: intercellular adhesion molecule-1; IFN-γ: interferon-γ; IL:
interleukin; I/R: ischemia/reperfusion; CDK5: cyclin-dependent kinase 5; SOD: superoxide dismutase; MDA: malondialdehyde; CaMKII: calmodulin-dependent protein kinase II;
CREB: cyclic adenosine monophosphate responsive element binding protein; Kv channels: voltage-gated potassium channels; VCAM-1: vascular cell adhesion molecule-1; VLA-4:
very late antigen-4; LysM–EGFP: lysozyme M promoter driving expression of enhanced green fluorescent protein; cMCAO: coagulation of the distal middle cerebral artery; fMCAO:
occlusion of the middle cerebral artery with an endovascular filament; CsA: cyclosporine A; MP: methylprednisolone; EPO: erythropoietin.
Int. J. Mol. Sci. 2016, 17, 1967 27 of 53
5.3. Fingolimod (FTY720)
Fingolimod is a sphingosine 1-phosphate receptor analogue preventing lymphocyte way out from
lymphoid organs [266]. Studies on mouse models showed that fingolimod was able to decrease cerebral
lymphocyte infiltration, limit the hemorrhagic transformation and the BBB breakdown, and reduce the
levels of ICAM-1, IFN-γ, and IL-17 [214,239]. A systematic review advised to consider with caution
fingolimod as a potential drug for IS as more good quality experimental studies evaluating its safety
as well as its efficacy in old animals mimicking human comorbidities were needed [267]. Induction of
lymphocytopenia and reduction of microvascular thrombosis seemed to be the main mechanisms of
action of fingolimod [268].
5.4. Donepezil
Donepezil is a central acetylcholinesterase inhibitor. In different animal models, donepezil was
demonstrated to decrease ischemic injury probably via the nicotinic acetylcholine-receptor signaling
and the Kv2.1 potassium channels [231,244,252]. Other neuroprotective properties of donepezil have
been described, such as the attenuation of the excitotoxic damage induced by membrane depolarization,
the improvement of cognitive dysfunction after chronic cerebral hypoperfusion, and the reduction of
systemic inflammatory responses via the blocking of cytokine release and cyclooxygenase-2 expression
in the brain [210,225,269].
5.5. Citalopram
Citalopram is a selective serotonin re-uptake inhibitor mainly used as antidepressant drug.
In mice, citalopram was demonstrated to improve neurovascular regeneration and functional recovery
following IS [220]. The main explanation of these effects could be its anti-inflammatory effects,
as demonstrated in a focal brain ischemia rat model in which citalopram was able to down-regulate
various inflammatory cytokines, such as IL-1β and TNF-α [270]. Delayed degeneration of
dopaminergic neurons following brain ischemia was demonstrated to be reversed by citalopram [223].
Citalopram was described to reduce glutamate and d-serine release from LPS-activated microglia
leading to an improvement in the survival of OGD-injured cortical neurons [271].
5.6. Natalizumab (Anti-CD49d Antibody)
Natalizumab is a humanized monoclonal antibody recognizing the α4 integrin currently used
in multiple sclerosis and Crohn’s disease. In 2001, for the first time, beneficial effects of anti-CD49 d
antibody both before or immediately after MCAO were reported showing a reduction of the volume
of the ischemic lesion and an improvement of the neurological outcome [213,237]. In stroke models,
very late antigen (VLA)-4 blockade before or after 3 h after induction of cerebral ischemia was found to
improve the outcome because of a reduced lymphocyte invasion in the brain and neurotoxic cytokine
production. Furthermore, VLA-4 inhibition resulted in a reduction of the post-ischemic VCAM-1
up-regulation. These findings supported the concept that invading T cells via their humoral secretion
(IFN-γ) and cytotoxic mechanisms (perforin) played a pivotal role in the pathways leading to delayed
post-ischemic tissue injury [226]. On the contrary, Langhauser and colleagues demonstrated that
pharmacological inhibition of the VLA-4/VCAM-1 axis with anti-CD49d antibody in experimental
stroke failed and raised doubts on the effectiveness of anti-CD49d as a stroke treatment [224]. Different
studies supported the pathogenic role of infiltrating T-cells as their blockage could be a turning
point for the neuroprotective effects of anti-CD49d antibody without considering other cell types
as possible relevant players. For this reason, Neumann and colleagues showed that the beneficial
effects of post-stroke anti-CD49d therapy could be brought by the inhibition of both neutrophils
and lymphocytes trafficking into the brain parenchyma [232]. Llovera and co-workers performed
a preclinical randomized controlled multicenter trial in order to evaluate the efficacy of anti-CD49d
treatment and found different effects according to different stroke models [230]. In particular,
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the blockage of CD49d decreased infarct size in animals suffering from permanent MCAO, but did not
influence the lesion in animals suffering from a transient MCAO [230].
5.7. Cyclosporine A
Cyclosporine A owns immunosuppressive activity, but can also reduce infarct size in animal
models of brain ischemia, markedly ameliorating delayed neuronal damage as it passes the BBB,
maybe with the involvement of calcineurin [217,243,250,253]. Cyclosporine A was demonstrated to
block the way of the nuclear factor of activated T cell family group of transcription factors to the
nucleus leading to a specific inhibition of IL production in T cells [272]. In rodent models, cyclosporine
A was found to reduce ischemic cerebral lesions, ROS production, and cerebral vasospasm following
subarachnoid hemorrhage [217,273]. Moreover, cyclosporine A was described to block T-cell activation
and cytokine production.
5.8. Edaravone (MCI-186)
Edaravone is an antioxidant and ROS scavenger. In a rat transient focal ischemia model, edaravone
showed a minor infarct volume and edema compared with control group after 24 h from stroke. Besides,
it was able to decrease IL-1β and MMP-9 levels as well as many others, such as fractalkine, IL-1α,
IL-1Ra, IL-6, IL-10, macrophage inhibitory protein (MIP)-1α and MIP-3α [221]. These beneficial effects
in terms of infarct volume and hemorrhagic transformation decrease were demonstrated also in IS
rats with hyperglycemia [274]. Edaravone was found to greatly accelerate thrombolysis by alteplase
in an experimental thrombosis model [248]. In another experimental thrombotic stroke, Sun and
colleagues found that t-PA at 0.5 or 1 h reduced infarction volume showing both synergistic and
additive benefits with edaravone treatment [275]. The acute, combined treatment led to more than
50% mortality reduction, nearly 80% infarct size decrease, strong white-matter protection, vascular
reperfusion improvement, oxidative stress, inflammatory cytokine, and matrix metalloproteinase
activity reduction [275]. In a rodent model of stroke, tempol and edaravone were tested to evaluate the
extent of glutamate and aspartate release. Tempol, but not edaravone, reduced the amino acid release
by 60%–80% as well as an intra-cerebroventricular injection of tempol, but not edaravone, decreased
infarction size by nearly 50% improving neurobehavioral outcomes. Interestingly, in vitro assays
demonstrated that tempol was superior in eliminating superoxide anion, whilst edaravone was more
efficient in scavenging hydrogen peroxide, hydroxyl radical, and peroxynitrite [276]. In a rat model
of transient cerebral I/R, the combination of edaravone and borneol significantly improved ischemic
injury demonstrating a synergistic effect, which led to reduced levels of pro-inflammatory mediators
and free radicals. This combination showed a therapeutic time window of 6 h in the present model
and significantly ameliorated injury also in permanent ischemia model. Surprisingly, the combination
triggered long-term effect, such as improvement in elemental vital signs, sensorimotor functions,
and spatial cognition [245].
6. Anti-Inflammatory Treatments in IS: Evidence from Clinical Trials
In light of the beneficial effects of some anti-inflammatory treatments experimented in animal
models, some of these compounds were tested in humans in phase II or III clinical trials in the setting
of IS (Table 6) [277–295].
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Table 6. Randomized clinical trials in ischemic stroke.
Study Year Treatment Sample Size Outcome
IL-1Ra
Emsley et al. [283] 2005
Within 6 h of the stroke onset,
patients were randomized to rhIL-1ra
(intravenously by a 100 mg loading dose
over 60 s, followed by a 2 mg/kg/h
infusion over 72 h.) or placebo.
34 patients (17 rhIL-1Ra, 17 placebo)
Peripheral total white blood cell and neutrophil count,
CRP, and IL-6 and neutrophil counts were lower in the
rhIL-1ra-treated were lower in the treated group. The drug
was safe and well tolerated.
Smith et al. [294] 2012
Blood samples prior to treatment
initiation, at 24 h and 5 to 7 days. LPS
stimulation was made to assess cytokine
production by leukocytes.
34 patients (17 rhIL-1Ra, 17 placebo)
Induction of TNF-α (p < 0.001), IL-1β (p < 0.005), IL-6, IL-8, and
IL-10 (p < 0.02) by LPS was reduced in patients at admission. At
24 h, for patients treated with IL-1Ra, induction of TNF-α, IL-6
and IL-10 was greater than in the placebo group (p < 0.05). At 5
to 7 day, TNF-α and IL-1β induction remained suppressed only
in the placebo group (p < 0.05). Plasma cortisol concentrations
were elevated at admission in patients compared to controls but
decreased at 24 h in treated patients (p < 0.05) and inversely




Survival Study (4S) [277] 1994
Patients with angina pectoris or previous
MI and serum cholesterol 5.5–8.0 mmol/L
on a lipid-lowering diet were randomized
to double-blind treatment with
simvastatin or placebo.
4444 patients (2221 simvastatin, 2223
placebo)
Over 5.4 years, simvastatin improved lipid profile, with few
adverse effects. The relative risk of death in the simvastatin
group was 0.70 (95% CI 0.58–0.85, p = 0.0003). In a post hoc
analysis, simvastatin was demonstrated to reduce by 30%
the rate of strokes and transient ischemic attacks.
Plehn et al. [290] 1999
Enrolled patients: 21–75 years old who
had experienced a myocardial infarction
within the past 3 to 20 months, total
cholesterol <240 mg/dL, LDL cholesterol
between 115 and 174 mg/dL, and fasting
triglycerides <350 mg/dL during
4 weeks of treatment.
4159 patients (2081 pravastatin 40 mg
daily and 2078 placebo)
Compared with placebo, pravastatin lowered total and LDL
cholesterol, and triglycerides by 20%, 32%, and 14%,
respectively. A total of 128 strokes (52 on pravastatin, 76 on
placebo) and 216 strokes or TIAs (92 on pravastatin, 124 on
placebo) were observed, representing a 32% reduction (95% CI,
4%–52%, p = 0.03) in all-cause stroke and 27% reduction in
stroke or TIA (95% CI, 4%–44%, p = 0.02). No increase in
hemorrhagic stroke with pravastatin was found.
Montaner et al. [288] 2008
Simvastatin (40 mg/day for the first
week followed by a dose of 20 mg/day
until day 90) or placebo were given at
3–12 h from symptom onset.
60 patients (30 simvastatin, 30 placebo)
Simvastatin-treated group presented greater improvements at
several time points (p = 0.01). Simvastatin treatment and low
temperatures were the only independent predictors of a great
improvement by day 90 (OR 10.3, CI 2.05–52.2, p = 0.005 and
OR 0.13, CI 0.02–0.70, p = 0.017, respectively).
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Sever et al. [292] 2003
Hypertensive patients aged 40–79 years
with at least 3 other cardiovascular
risk factors.
10305 (5168 atorvastatin 10 mg daily
and 5137 placebo)
Treatment was stopped after a median follow-up of 3.3 years.
In the atorvastatin group, less primary events occurred
(HR 0.64, 95% CI 0.50–0.83, p = 0.0005), especially in the first
year of follow-up. Fatal and non-fatal stroke (p = 0.024), total
cardiovascular events and total coronary events (p = 0.0005)
were also lowered.
Amarenco et al. [278] 2006
Patients with previous stroke or TIA
within one to six months, LDL
cholesterol levels of 100 to 190 mg/dL,
and no known coronary heart disease.
4731 patients (2365 atorvastatin 80 mg
daily and 2366 placebo)
During 4.9 years, 265 patients under atorvastatin and 311 under
placebo had a fatal or non-fatal stroke (5-year absolute
reduction in risk, 2.2%; adjusted HR 0.84, 95% CI, 0.71–0.99,
p = 0.03; unadjusted p = 0.05). The 5-year absolute reduction in
the risk of major cardiovascular events was 3.5% (HR, 0.80,
95% CI, 0.69–0.92, p = 0.002). No difference in mortality rate
was seen.
Shepherd et al. [293] 2002 Patients aged 70–82 years with a historyof or risk factors for vascular disease.
5804 patients (2891 pravastatin 40 mg
daily and 2913 placebo)
Pravastatin lowered LDL cholesterol and reduced the incidence
of the primary endpoint (HR 0.85, 95% CI 0.74–0.97, p = 0.014).
Coronary heart disease death and non-fatal MI risk was also
reduced (p = 0.006). Stroke risk was unaffected (p = 0.8) as well
as for TIA (p = 0.051). New cancer diagnosis were more frequent
in pravastatin group (p = 0.020). Mortality from coronary heart
disease was lower in the pravastatin group (p = 0.043). No
significant effect on cognitive function or disability was found.
Ridker et al. [291] 2008
Apparently healthy men and women
with LDL cholesterol levels of less than
130 mg/dL and hs-CRP levels of
2.0 mg/L or higher.
17802 patients (8901 rosuvastatin 20 mg
daily and 8901 placebo)
Rosuvastatin reduced LDL cholesterol levels and hs-CRP levels.
Rates of occurrence of the combined primary end point (MI,
stroke, arterial revascularization, hospitalization for unstable
angina, or death from cardiovascular causes) were 0.77 for
rosuvastatin (HR 0.56, 95% CI: 0.46–0.69, p < 0.00001; HR for
stroke 0.52, 95% CI 0.34–0.79, p = 0.002).
Donepezil
Barrett et al. [280] 2011 Adults with ischemic stroke treatedwithin 24 h after onset of symptoms.
33 patients receiving donepezil 5 mg
daily for 30 days followed by an
increase to 10 mg/day for 60 days
15 participants had a favorable clinical outcome (NIHSS
score ≤1 at day 90) (p < 0.001).
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Cyclosporine A
Nighoghossian et al. [289] 2015
Patients aged 18–85 years with an
anterior-circulation stroke and eligible for
thrombolytic therapy and evaluation of
infarct volume on MRI at 30 days.
127 patients (61 CsA 2 mg/kg and
66 saline)
The reduction of infarct volume in CsA-treated patients was not
significant (p = 0.18). In patients with proximal occlusion and
effective recanalization, infarct volume decreased in





2003 Patients with acute ischemic strokewithin 72 h from symptom onset.
250 patients (125 edaravone
30 mg twice a day for 14 days
and 125 placebo)
A significant improvement in functional outcome evaluated by
the mRS was observed in the edaravone group (p = 0.039).
Kaste et al. [284] 2013 Patients with acute ischemic strokewithin 24 h from stroke onset.
36 patients (12 edaravone with loading
dose 0.08 mg/kg + 0.2 mg/kg/h; 13
edaravone loading dose 0.16 mg/kg +
0.4 mg/kg/h; 11 placebo)
Both doses of the new formulation and dosing regimen were
well tolerated and showed clinical improvement based on
NIHSS score.
Takenaka et al. [295] 2014
Patients admitted to hospital for cerebral
infarction within 3 h after the onset of
infarction.
48 patients (20 edaravone before
rt-PA and 28 edaravone and
rt-PA simultaneously)
NIHSS before rt-PA showed a statistically significant
improvement after rt-PA administration (p < 0.001).
The mRS at 90 days also improved.
rhIL-1Ra: recombinant human IL-1 receptor antagonist. LPS: lipopolysaccharide. TNF-α: tumor necrosis factor-α. IL: interleukin. MI: myocardial infarction. LDL: low density
lipoprotein. TIA: transient ischemic attack. CI: confidence interval. OR: odds ratio. HR: hazard ratio. Hs-CRP: high sensitivity C-reactive protein. NIHSS: National Institute of Health
Stroke Scale. CsA: cyclosporine A. MRI: magnetic resonance imaging. mRS: modified Rankin scale. rt-PA: recombinant tissue-type plasminogen activator.
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6.1. IL1-Ra
Anakinra is the recombinant form of human IL-1Ra and has a half-life of 5–6 h. In a phase II
RCT, patients within 6 h of the onset of symptoms of IS were randomized to anakinra or placebo
intravenously by a 100 mg loading dose over 60 s, followed by a 2 mg/kg/h infusion over 72 h [283].
Neutrophil and total white cell counts, CRP, and IL-6 concentrations were lower in anakinra-treated
patients; moreover, among patients with cortical infarcts, clinical outcomes at 3 months in the
anakinra-treated group were better than in placebo-treated. Over the follow-up period, no adverse
events were recorded. In secondary analyses, Smith and colleagues investigated whether the
administration of IL-1Ra to patients with IS affected innate cellular immune responses [294]. Induction
of TNF-α, IL-1β, IL-6, IL-8, and IL-10 by LPS was significantly reduced in patients at admission, prior to
treatment with anakinra or placebo, with respect to controls. While in the placebo group the cytokine
induction remained suppressed over the entire week of follow-up, in anakinra-treated patients the
suppression of this induction was reversed. The authors concluded that IL-1Ra might be able to
reverse peripheral innate immune suppression in the acute phase of IS by blocking IL-1-correlated
pathways. Currently, the Subcutaneous interleukin-1 receptor antagonist (SC IL-1RA) in Stroke Study,
a phase II RCT, is investigating the effects of anakinra subcutaneously in the setting of IS (available at:
http://www.isrctn.com/ISRCTN74236229). The recruitment started in November 2013 and ended in
April 2016 with participants receiving anakinra subcutaneously twice daily for 72 h or placebo; the first
injection of IL-1Ra was given within 6 h from stroke onset with 5 more doses at 12 h intervals for
3 days. The primary endpoint was to evaluate the reduction in inflammatory biomarker levels between
6 h and 5–7 days after stroke. Finally, canakinumab is a human monoclonal antibody selectively
targeting IL-1β with a half-life of 21–28 days, which promisingly gains great interest as treatment for
IS patients [296].
6.2. Statins
Beneficial effects of statins in atherosclerosis are by now well known. Beyond cholesterol lowering,
statins have been shown to own many anti-inflammatory and antioxidant activities by modulating
inflammatory pathways involving kinase phosphorylation and protein prenylation [297]. In a post hoc
analysis of the Scandinavian Simvastatin Survival Study, simvastatin was demonstrated to reduce by
30% the rate of strokes and transient ischemic attacks [277]. Pravastatin was found to reduce by nearly
30% stroke incidence after myocardial infarction, with a reduction involving all kind of strokes and
a similar treatment effect when adjusted for age, sex, history of hypertension, cigarette smoking,
diabetes, left ventricular ejection fraction, and baseline cholesterol and triglyceride levels [290].
In a more recent study, simvastatin was tested in the acute phase of IS (3–12 h from symptom onset)
showing improvement in neurological scales at several time-points, even if no clear mechanism was
found due to the lack of effect on analyzed biomarkers (IL-6, IL-8, IL-10, MCP-1, ICAM-1, VCAM-1,
CRP, selectins, and TNF-α) [288]. Collins and co-workers showed that simvastatin 40 mg daily was
highly effective in reducing the rate of ischemic strokes in patients with cerebrovascular disease or
another occlusive arterial disease or diabetes; the reduction in stroke occurrence was significant by the
end of the second year [298]. Recently, Montaner and co-workers did not show any improvement in
neurological or functional outcome when patients were treated with simvastatin [299]. In addition,
in this study, the combination therapy of simvastatin with tPA in acute IS was proven to be safe, showing
low rates of bleeding complications [299]. In the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid
Lowering Arm, 19,342 hypertensive patients with normal lipids and at least three cardiovascular
risk factors were administered atorvastatin 10 mg daily or placebo, but the trial was early stopped
after 3.3 years because of great benefits in the treatment arm, that is a 27% reduction of fatal and
non-fatal strokes [292]. In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels
trial, patients with recent stroke or transient ischemic attack without known coronary heart disease
were administered atorvastatin 80 mg daily showing a reduction in stroke incidence and overall
cardiovascular events, by 16% and 10% respectively, despite a small increase in the incidence of
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hemorrhagic stroke [278]. The Long Term Intervention with Pravastatin in Ischemic Stroke Study
included patients with myocardial infarction/unstable angina and an initial total cholesterol of 155
to 270 mg/dL under pravastatin 40 mg daily or placebo. After a 6 year-follow-up, pravastatin
demonstrated a 23% relative reduction in risk from non-hemorrhagic stroke [300]. In the Myocardial
Ischemia Reduction with Aggressive Cholesterol Lowering sub-study, intensive treatment with
atorvastatin over 16 weeks in patients with acute coronary syndromes was found to decrease the overall
stroke rate by half without causing hemorrhagic stroke [301]. The PROspective Study of Pravastatin
in the Elderly at Risk trial and the GREek Atorvastatin and Coronary-heart-disease Evaluation trial
showed more weak results [293,302]. In a predetermined pooled analysis of almost 2000 patients with
evidence of atherosclerosis and elevated lipid levels, pravastatin was found to reduce by 62% the stroke
rate [303]. In the JUPITER trial, apparently healthy people without hyperlipidemia and with elevated
high-sensitivity CRP levels were administered rosuvastatin 20 mg daily highlighting a significant
reduction in the incidence of major cardiovascular events (33% reduction in the primary end point); in
particular, the effect for stroke was very consistent (hazard ratio 0.52, 95% confidence interval 0.34–0.79,
p = 0.002) and was observed in all subgroups evaluated [291]. Recently, rosuvastatin 20 mg daily
demonstrated to have poor effects in reducing the recurrence of IS in statin-naïve patients. No difference
between rosuvastatin and placebo was found for the frequency of new ischemic lesions and infarct
volume growth at 5 days on MRI, although hemorrhagic complications occurred less frequently in
the rosuvastatin group [304]. Premorbid statin users have been shown both less frequent plaque
enhancement and lower enhancement volume, which is a marker of plaque instability. Interestingly,
lower degree of plaque enhancement together with antecedent statin use were mainly correlated
to a higher frequency of non-embolic lesion pattern, suggesting that statin therapy could reduce
large cortical infarcts by stabilizing intracranial atherosclerotic plaque. Moreover, the proportion of
IS due to plaque rupture was lower among premorbid statin users. Unfortunately, no evaluation
was done with regard to the impact of statins on the reduction of the incidence of IS in patients
with intracranial atherosclerosis and no clinical improvement was highlighted among premorbid
statin-treated patients at 90 days after IS [305]. Many observations demonstrated that pre-treatment
with statins improves stroke outcome at 90 days and this benefit is evident across all the stroke
subtypes [306,307], as confirmed by the meta-analysis by Biffi et al., especially in patients with small
vessel stroke disease, and Ní Chróinín et al. [308]. As further proof of it, patients discontinuing statins
even for short periods have been described to have a worse outcome and increased mortality [309].
The systematic review by Squizzato and co-workers concluded that data from RCTs were
insufficient to consider statins as safe and effective drugs for IS [310]. A more recent systematic
review by Hong et al. dealt with different aspects of statin treatment in IS [311]. Although no
evidence of a benefit from statin treatment globally emerged from RCTs, the available data provided
some interesting elements. First of all, pre-stroke statin therapy was confirmed to be beneficial in
terms of reduced ischemic brain damage at the onset, functional outcome, and short-term mortality.
Secondly, immediate post-stroke statin treatment could reduce functional disability and short-term
mortality and supported the worsening of the outcome in case of withdrawal; the effect on short-term
mortality could be related to the prevention of recurrent ischemic brain events. Thirdly, patients
treated with thrombolysis gained a better outcome if treated with statins in spite of a certain increase
in hemorrhagic complications. For this reason, some concerns have been raised by neurologists for
statin use in IS patients undergoing thrombolysis [312]. The meta-analysis by Hong et al. [311] showed
an increased risk for hemorrhagic transformation, as shown before, but also confirmed an improvement
of the functional outcome with statin therapy, in contrast with previous meta-analyses [308,313,314],
concluding that statins are not to be considered a contraindication for thrombolysis [311].
6.3. Fingolimod (FTY720)
Oral fingolimod (FTY720) is currently under investigation in a phase II randomized, open-label
study including patients within 72 h of IS or spontaneous intracranial hemorrhage (available at:
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https://clinicaltrials.gov/ct2/show/NCT02002390). Primary outcome measures were clinical
improvement up to 90 days, while secondary outcome measures were change in image and in
immunology function up to 90 days. Considering the side effects of fingolimod, such as infections and
cardiac rhythm alterations, the translational use of this drug could be limited in IS patients [315].
6.4. Donepezil
Exploiting the promising effects of donepezil in pre-clinical studies, the Mayo Acute Stroke Trial
for Enhancing Recovery was designed to test the safety and tolerability of donepezil within 24 h
from IS [280]. Donepezil was demonstrated to be safe and well tolerated with no treatment-related
serious adverse events registered. Moreover, donepezil was shown to lead to cognitive improvements
maybe through the increase in basal forebrain cholinergic systems, but these results are needed to
be considered with caution in absence of a placebo-controlled comparison group. Donepezil was
successfully tested as therapeutic choice for the treatment of Wernicke aphasia following a recent
infarction in the right middle cerebral artery in a 53-year woman [316]. Donepezil has been proven
effective in the re-organization of the cognitive neural network in patients with post-stroke cognitive
impairment using functional MRI by increasing the activation of pre-frontal areas, inferior frontal
lobes, and the left inferior parietal lobe [317].
6.5. Citalopram
TALOS is an ongoing, multicentre, randomized- and placebo-controlled, double-blind trial of
citalopram in patients with IS comparing citalopram 10–40 mg daily and placebo within 7 days
of first IS over a 6-month follow-up period (available at: https://clinicaltrials.gov/ct2/show/
NCT01937182) [318]. The primary end point includes a composite outcome with vascular death,
transient ischemic attack/stroke, and myocardial infarction and a functional outcome at 6 months
evaluated by the modified Rankin scale. The secondary end point includes vascular mortality,
all-cause death, stroke, bleeding, cognitive and organic cerebral impairment, post-stroke depression,
pathological crying, and lesion size. No result is yet available, even if the restriction to first-ever stroke
and the exclusion of patients with dementia could reduce the translational impact of this work.
6.6. Natalizumab (Anti-CD49d Antibody)
The ACTION trial (available at: https://clinicaltrials.gov/ct2/show/NCT01955707) is
a multicenter, double-blind, placebo- and randomized-controlled study to evaluate the safety and
efficacy of intravenous natalizumab on the reduction of infarct volume in IS. The final results were
recently disclosed at the International Stroke Conference in Los Angeles in February 2016 showing
the safety of this therapy. In IS patients, a single dose of natalizumab (300 mg intravenously) between
0 and 9 h did not change infarct volume from baseline to day 5 on MRI, but surprisingly functional
outcomes measured by modified Rankin scale and Barthel index improved at day 90 [319].
6.7. Cyclosporine A
The Neuroprotection Impact of Cyclosporine A in Cerebral Infarction (available at:
https://clinicaltrials.gov/ct2/show/NCT01527240) is a phase II study testing a single dose of
cyclosporine A intravenously versus placebo on MRI infarct volume at 30 days in thrombolysed
patients within 4.5 h from stroke symptom onset; the trial was completed but no result is still available.
In a phase II, pilot study, cyclosporine A intravenously (2.0 mg/kg) combined with thrombolysis was
evaluated in 127 IS patients. The primary end point was infarct volume on MRI at 30 days, whilst
secondary end points were infarct volume according to the site of occlusion and recanalization after
thrombolysis. Cyclosporin A demonstrated to be safe but failed to reduce the final infarct size; only in
the subgroup of patients with proximal occlusion and successful recanalization, cyclosporine A did
reduce infarct volume [289].
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6.8. Edaravone (MCI-186)
Currently, MCI-186 is the one neuroprotectant candidate approved for the treatment of IS
patients in Japan, but its use is restricted as grade B recommendation by Japanese guidelines [320].
This recommendation was based on a small Japanese RCT including edaravone 30 mg twice daily
within a 72 h window [282]. Edaravone 30 mg twice daily was compared to ozagrel and showed
non-inferiority in terms of functional outcomes in a multicenter, phase 4 randomized, open-label
trial [321]. Edaravone was tested in an European double-blind, placebo-controlled RCT using two dosing
regimens (loading dose 0.08 mg/kg + 0.2 mg/kg/h infusion or loading dose 0.16 mg/kg + 0.4 mg/kg/h
infusion). No concerns on safety and tolerability were raised and therapeutic range was reached
consistently during the infusion period [284]. Edaravone was found to abrogate MMP-9 levels in
patients with IS [322,323]. As previously found in experimental models [274], in diabetic patients
edaravone showed to significantly decrease NIHSS and Barthel index; moreover, the incidence
of hemorrhage transformation, pulmonary infection, recurrent stroke, and seizures was markedly
reduced [324]. In light of pre-clinical evidence [248,275], the combined therapy with recombinant
t-PA and edaravone improved the recanalization rate, reduced the intracranial hemorrhage incidence,
and ameliorated functional prognosis [295].
7. Conclusions
IS remains a great burden in modern society. Despite great clinical progresses having been
made in recent years in order to improve diagnosis and treatment, beneficial long-term interventions,
especially with regard to recovery, are still not available. We now know that the abrupt, dramatic
inflammatory response immediately following IS can be evaluated as central or peripheral based
on the brain or peripheral tissue origin. In recent years, our knowledge about macrophages has
grown considerably as we now can consider M1 and M2 macrophage responses in the post-ischemic
period. The spleen has gained great attention as a reservoir of inflammatory cells and cytokines
released in the bloodstream following IS. Apart from widely known cytokines, chemokines, DAMPs,
and autoantibodies as well as OPG and OPN represent important inflammatory mediators in the
ischemic milieu and need to be considered in a therapeutic perspective. In addition to old therapies,
such as statins, new treatments are being introduced, such as monoclonal antibodies, fingolimod,
cyclosporine A, and edavarone showing promising results in pre-clinical studies and partly in phase 2
and 3 studies; nevertheless, much more efforts are needed. Notably, even if still under investigation,
cell-based therapies may potentially become useful for other neurological diseases other than stroke.
Bone marrow, human umbilical cord blood, and neural cells as well as adipose tissue-derived stromal
cells could be therapeutic targets for the future, exploiting common mechanisms, such as paracrine
release and immunomodulation [325]. We also need to increase our knowledge about currently known
mediators, such as cytokines, given that the current approach is based on blocking of pro-inflammatory
cytokines or supplement of anti-inflammatory cytokines [326]. Further trials are suggested in order
to obtain more information on cytokine profile in order to appropriately select therapy according to
each patient. Finally, inflammation is also needed for appropriate post-stroke recovery. Therefore,
the potential risk of abrogating inflammation might per se raise some concerns on the safety of this
therapeutic strategy. Future clinical studies investigating these aspects are welcomed.
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